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New Methods in Cardiovascular Biology
Terminal Differentiation, Advanced Organotypic
Maturation, and Modeling of Hypertrophic Growth in
Engineered Heart Tissue
Malte Tiburcy,* Michael Didie´,* Oliver Boy, Peter Christalla, Stephan Döker, Hiroshi Naito,
Bijoy Chandapillai Karikkineth, Ali El-Armouche, Michael Grimm, Monika Nose,
Thomas Eschenhagen, Anke Zieseniss, Doerthe M. Katschinski, Nazha Hamdani, Wolfgang A. Linke,
Xiaoke Yin, Manuel Mayr, Wolfram-Hubertus Zimmermann
Rationale: Cardiac tissue engineering should provide “realistic” in vitro heart muscle models and surrogate tissue
for myocardial repair. For either application, engineered myocardium should display features of native
myocardium, including terminal differentiation, organotypic maturation, and hypertrophic growth.
Objective: To test the hypothesis that 3D-engineered heart tissue (EHT) culture supports (1) terminal differenti-
ation as well as (2) organotypic assembly and maturation of immature cardiomyocytes, and (3) constitutes a
methodological platform to investigate mechanisms underlying hypertrophic growth.
Methods and Results: We generated EHTs from neonatal rat cardiomyocytes and compared morphological and
molecular properties of EHT and native myocardium from fetal, neonatal, and adult rats. We made the following
key observations: cardiomyocytes in EHT (1) gained a high level of binucleation in the absence of notable
cytokinesis, (2) regained a rod-shape and anisotropic sarcomere organization, (3) demonstrated a fetal-to-adult
gene expression pattern, and (4) responded to distinct hypertrophic stimuli with concentric or eccentric
hypertrophy and reexpression of fetal genes. The process of terminal differentiation and maturation (culture
days 7–12) was preceded by a tissue consolidation phase (culture days 0–7) with substantial cardiomyocyte
apoptosis and dynamic extracellular matrix restructuring.
Conclusions: This study documents the propensity of immature cardiomyocytes to terminally differentiate and
mature in EHT in a remarkably organotypic manner. It moreover provides the rationale for the utility of the EHT
technology as a methodological bridge between 2D cell culture and animal models. (Circ Res. 2011;109:1105-1114.)
Key Words: cardiac myocytes  caspase activation  extracellular matrix  maturation  hypertrophy  sarcomere
 tissue engineering
Different myocardial tissue engineering formats havebeen developed throughout the past decade.1 However,
a low degree of cell maturation remains a key caveat in
cardiac muscle engineering. A detailed understanding of
“developmental” processes in tissue engineered myocardium
probably is essential to guide tissue formation and maturation
in vitro and to enhance the applicability of tissue engineered
myocardium in substance screening, target validation, and
tissue repair.
Normal heart muscle growth encompasses processes of
terminal differentiation and maturation by hypertrophic
growth, leading to the formation of binucleated and rod-
shaped myocytes.2 Physiological maturation entails a charac-
teristic shift in gene expression, including a reduction of
transcripts encoding for fetal isoforms of myofibrillar pro-
teins while the proportion of adult isoforms increases.3
Terminal differentiation, for example, withdrawal from the
cell cycle, is another hallmark of advanced maturation al-
ready reached very early during development.4
Cardiomyocyte monolayer cultures show neither the dis-
tinct morphological (rod-shaped) nor the molecular (adult
gene expression program) make-up of mature myocytes,5–7
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probably as a consequence of the lack of a 3D growth
environment and inappropriate biomechanical loading. De-
spite some evidence for advanced maturation in 3D tissue
engineering models, it remains unclear whether cardiomyo-
cytes in tissue engineered myocardium can, and if so to what
extent, develop “physiologically” ex vivo.8,9
Three fundamentally different myocardial tissue engineer-
ing concepts are presently explored: (1) the classic approach
involves cell seeding on preformed scaffold material10–14; (2)
an alternative strategy is based on stacking cell sheets to
generate multilayered muscle constructs15; (3) we have de-
veloped another method, taking advantage of the inherent
capacity of immature cardiomyocytes to reassemble into
spontaneously beating tissue if maintained at high density in
a spatially defined culture environment under defined
load.9,16,17 This cell entrapment method was further refined
yielding engineered heart tissues (EHTs) with functional
properties of native myocardium.9
In the present study, we demonstrate that EHT cultures can
support terminal differentiation and tissue-like cardiomyo-
cyte maturation. This finding is underscored by the similarity
of morphological and molecular features of EHT- and post-
natal heart-derived cardiomyocytes. Interestingly, the process
of cardiomyocyte maturation and EHT-development showed
2 distinct phases: (1) a consolidation phase during culture
days 0–7 with high levels of apoptotic cell death as well as
extracellular matrix (ECM) degradation and (2) a maturation
phase during culture days 7–12 with myocyte binucleation,
formation of anisotropically organized sarcomeres in prefer-
entially rod-shaped cardiomyocytes, a shift from fetal-
skeletal to adult-cardiac actin transcript expression, and ECM
build-up. Exposure to different hypertrophic stimuli during
the maturation phase elicited distinct hypertrophic pheno-
types, that is, concentric or eccentric hypertrophy.
Methods
EHT Construction
EHTs were prepared from collagen type I, Matrigel, as well as
neonatal rat heart cells (2.5106) and cultured for 12 days.9
3H-Thymidine Incorporation
EHTs were labeled with 1 Ci/mL 3H-thymidine for 6 hours on the
indicated culture days. DNA was prepared using standard procedures
and subjected to liquid scintillation counting.
Cell Isolation
EHTs or hearts were digested with Liberase Blendzyme III in the
presence of 30 mmol/L 2,3-butanedione monoxime at 37°C to
prepare cardiomyocytes for morphological assessment by confocal
laser scanning microscopy and flow cytometry.
One-Dimensional Electrophoresis
and Immunoblotting
EHT protein was separated by SDS-PAGE. For detection of myosin
heavy chain (MHC), isoforms gels were stained overnight with
SYPRO Ruby. Blots were probed with monoclonal antibodies
directed against indicated proteins and developed with ECL-plus.
Two-Dimensional Electrophoresis and Nanoflow
Liquid Chromatography Tandem
Mass Spectrometry
Protein extracts were separated by 2D electrophoresis. Protein spots
were excised and enzymatically degraded. Peptides were separated
by a nanoflow HPLC system on a reverse-phase column and applied
to an LTQ ion-trap mass spectrometer.
3H-Phenylalanine and 3H-Proline Incorporation
EHTs were labeled with 1 Ci/mL 3H-phenylalanine or 3H-proline
as indicated. Protein was precipitated in 10% ice-cold trichloroacetic
acid at 4°C overnight and subjected to liquid scintillation counting.
35S-Cysteine/-Methionine Incorporation
and Autoradiography
EHTs were labeled with 100 Ci/mL 35S-cysteine/-methionine for
18 hours on the indicated culture days and proteins were separated by
SDS-PAGE. Gels were stained with Coomassie blue, immersed in
Amplify Fluorographic solution (Amersham Biosciences), vacuum
dried, and subjected to autoradiography.
An expanded Methods section can be found online at
http://circres.ahajournals.org.
Results
Construction of Spontaneously Contracting EHT
We generated spontaneously contracting EHTs from an
initially liquid reconstitution mixture composed of enzymat-
ically dispersed neonatal rat heart cells, collagen type I, and
basement membrane proteins (Matrigel).9 Cell clusters within
condensing EHTs started to beat within 2–3 culture days
(Online Video I). On culture day 7, all EHTs contracted
spontaneously and in unison (Online Video II). After 12
culture days, EHTs demonstrated a solid composition and
vigorous contractions (Online Video III).
Hypertrophic Growth of Cardiomyocytes in EHT
The changes in EHT morphology and function prompted us
to assess indices of cell proliferation and hypertrophy. We
observed a marked reduction in cell number to 30% of the
input cells between EHT culture day 0 (day of EHT construc-
tion) and day 12 (2.5106 versus 0.80.03106 cells/EHT;
n10; Figure 1A). Despite the cell loss, DNA content
decreased only by 42% (453 versus 261 g/EHT; n17–
20; Figure 1B), implying a relative increase of DNA content
per cell (18 versus 32 pg DNA/cell on culture days 0 and
12, respectively). Further analysis of cardiomyocyte (-
actinin–positive; Online Figure I, A) and fibroblast
(vimentin-positive; Online Figure I, B) quantity indicated that
the initial cell loss was mainly the consequence of high
cardiomyocyte loss while fibroblast content remained stable
Non-standard Abbreviations and Acronyms
ANP atrial natriuretic peptide
DAPI 4,6-diamidino-2-phenylindole
ECM extracellular matrix
EHT engineered heart tissue
MHC myosin heavy chain
MLC2v myosin light chain, ventricular isoform
MMP matrix metalloprotease
PHD prolyl-4-hydroxylase domain enzyme
TIMP tissue inhibitor of MMP
VEGF vascular endothelial growth factor
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(Figure 1C). Cell cycle activity assessed by flow cytometry
after 4,6-diamidino-2-phenylindole (DAPI) labeling identi-
fied highest levels of DNA-synthesis in fibroblasts (171%)
and cardiomyocytes (90.2%) on culture day 0 with lower
but constant DNA synthesis levels during culture days 3–12
(fibroblasts: 7% to 10%; cardiomyocytes: 3% to 5%; n4–8;
Figure 1D). Interestingly, 3H-thymidine incorporation
dropped markedly (P0.05) during the first 24 hours of EHT
culture to increase first slowly (until culture day 5) and then
markedly (P0.05) on culture days 7–12 (Figure 1E). The
steep increase in DNA synthesis in the absence of increasing
cell numbers appeared to be the consequence of (1) cardio-
myocyte binucleation (372%; n4 EHTs, 30–40 cells
each; Figure 1F) and (2) enhanced nuclear DNA content
(polyploidy) in a subset of cardiomyocytes (2N: 141%,
n4) in advanced EHT cultures (Online Figure II). These
properties, together with a high RNA/DNA ratio and 3H-
phenylalanine incorporation (Online Figure III) appear to be
signs of terminal differentiation and hypertrophic growth,
suggesting advanced organotypic maturation in particular
during late EHT culture.
Apoptotic Cell Death in Early EHT
The marked cell loss in EHT (Figure 1A) led us to investigate
whether this was a consequence of apoptosis and represents a
particular shortcoming of EHT versus conventional 2D cul-
tures. Activated caspase-3, a surrogate for apoptosis, was
especially high during early EHT culture (Figure 2A and
Online Video IV). In agreement with this, high proapoptotic
bax (Figure 2B) and low antiapoptotic Bcl-2 (Figure 2C)
transcript abundances were observed, resulting in a markedly
elevated bax/Bcl-2 ratio (Figure 2D). Notably, parallel cul-
tures of EHT versus 2D showed similar levels of apoptosis
(analyzed by flow cytometry), Trypan blue exclusion, and
drop in cardiomyocyte number (Online Figure IV, A through
C), collectively arguing against a unique apoptotic burden in
EHT.
Lack of Evidence for Hypoxia in EHT
Hypoxia has been suggested as a limitation in tissue engi-
neering and could have triggered apoptotic cell death. Sur-
prisingly, we did not observe a regulation of highly sensitive
hypoxia-response genes, for example, prolyl-4-hydroxylase
domain isoforms 2 and 3 (prolyl-4-hydroxylase domain
enzyme; PHD2/PHD3) mRNA and hypoxia-inducible
factor-1 (HIF-1) protein (Figure 3A through 3C). This led
us to conclude that cells sensed normoxic conditions compa-
rable to physiological tissue conditions throughout EHT
culture and that elevated VEGF-A transcripts observed in late
EHT culture (Figure 3D) were unrelated to hypoxia.
Sarcomere Maturation in EHT
A hallmark of maturation in terminally differentiated cardio-
myocytes is the shift from a fetal to an adult gene expression
program. This encompasses an increase in -cardiac (-cd)
actin and a decrease in -skeletal (-sk) actin transcript
concentration10,18 as well as a shift from -(fetal/slow)-MHC
to -(adult/fast)-MHC in rodents.3,18 We could indeed ob-
serve an increase in -cd actin and a parallel decrease in -sk
actin transcripts (Figure 4A and 4B), leading to an overall
increase in total -sarcomeric actin protein in late EHT-
cultures (Figure 4C). In contrast, -MHC transcript expres-
sion was unchanged, whereas -MHC transcripts were ele-
vated, resulting in a lower -/-MHC transcript ratio in EHT
as compared with adult myocardium (72 versus 8819-
fold n10/9; Figure 4D through 4F). Notably, also on protein
level we identified a 40.8-fold (n8) -MHC excess in day
12 EHT (Figure 4F, inset). Direct comparison of atrial
natriuretic peptide (ANP), -sk actin, and -cd actin tran-
script abundance in monolayer and EHT cultures documented
that so called fetal genes (ANP, -sk actin) were more
abundant in monolayer as compared with EHT cultures
(Online Figure V).
Figure 1. Cell loss and DNA synthesis during EHT culture. A,
Cell number at the time of EHT casting (culture day 0) and on
subsequent culture days 3, 7, and 12 (n10/time point). B, DNA
content in EHTs on culture days 0 (n18), 3 (n20), 7 (n17),
and 12 (n20). C, Number of cardiomyocytes (actinin-positive
cells) and fibroblasts (vimentin-positive cells) at the time of EHT
casting (culture day 0, n8) and on subsequent culture days 3
(n4), 7 (n6), and 12 (n4), assessed by flow cytometry after
enzymatic dispersion of EHTs. D, DNA synthesis (S-phase) in
cardiomyocytes and fibroblasts in EHT on culture days 0 (n6),
3 (n4), 7 (n6), and 12 (n4), assessed by flow cytometry in
DAPI-stained actinin- and vimentin-positive cells. E,
3H-thymidine incorporation in EHTs on culture days 0, 1, 3, 5, 7,
9, 11, and 12 (n9/time point). F, Number of nuclei in neonatal
rat heart–derived (postnatal days 1–3, n60; white bar) and
EHT-derived myocytes on culture day 12 (black bars; n4
EHTs, 30–40 cells each); inset: example of a binucleated car-
diomyocyte: bar: 10 m. *P0.05 versus day 0 (A through C);
*P0.05 versus cardiomyocytes day 0 and §P0.05 versus
fibroblasts day 0 (D); ANOVA followed by Bonferroni multiple
comparison test.
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Dissection of the EHT Proteome
Increasing fluorescence intensity after -actinin immunola-
beling (in particular in day-12, EHT-derived cardiomyocytes;
Online Figure I, A) provided additional evidence for tissue
maturation. Subsequently, we performed proteome analyses
to obtain a more comprehensive snapshot of the EHT pro-
teome on culture days 0 and 12 (Figure 5A). The identity of
a select set of proteins was confirmed by mass spectrometry
(Online Table I). In agreement with the notion of advanced
organotypic and in particular ventricular maturation in EHT,
we observed a markedly enhanced level of the ventricular
isoform of myosin light chain (MLC2v) protein per cardio-
myocyte in day 12 versus day 0 EHTs (Figure 5B). Robust
detection of tropomyosin isoforms, desmin, and M-type
creatine kinase provided further evidence for the presence of
cardiomyocytes with an advanced degree of maturation.
Vimentin protein, characteristically expressed in fibroblasts,
did not significantly change during EHT culture (Figure 5C),
indicating phenotypic stability in this most abundant cellular
constituent of EHT.
Structural Properties of
EHT-Derived Cardiomyocytes
The shape and size of cardiomyocytes changed dramatically
during EHT maturation from round and unstructured directly
after isolation (mean diameter: 100.2 m; volume:
57032 m3, n60) to rod-shaped and clearly cross-striated
with sarcomeres in registry in 12-day-old EHTs (mean
diameter: 5.80.1 m, length: 722 m, volume:
2,040120 m3, n113; Figure 6). Compared with cardio-
myocytes from 12-day-old rats, EHT-derived cardiomyocytes
acquired a similar length but were thinner and consequently
less voluminous (mean diameter: 9.20.1 m, length:
671 m, volume: 4,724154 m3, n3 hearts, 80–100 cells
each; Figure 6). Myocytes from adult rats were clearly larger
than EHT- and 12-day-old, rat heart–derived myocytes (mean
Figure 2. Apoptosis as main cause of cell
death in EHT. A, Active caspase-3 (red) in
EHTs; bottom right: percentage of caspase-
positive cells at individual time points (green:
f-actin; blue: DAPI-labeled nuclei; bars: 50 m;
refer also to Online Video IV). B, Bax (n10/
time point), and C, Bcl-2 (n10/time point)
transcripts per GAPDH transcript. D, Bax/Bcl-2
transcript ratio(n10/time point). *P0.05 ver-
sus day 0; ANOVA followed by Bonferroni mul-
tiple comparison test.
Figure 3. Lack of signs of intense hypoxia in
EHT culture. A, PHD2, and B, PHD3 transcripts
per GAPDH transcript during EHT culture (n4/
time point). C, HIF-1 protein in EHT at different
time points in culture, in isolated cardiomyo-
cytes (CM), and cell free EHT matrix (CFM,
composed of collagen and Matrigel); note that
CFM is high in HIF-1 protein (extracellular),
which is gradually washed out during EHT cul-
ture; calsequestrin 2 (CSQ2) is displayed as
cardiomyocyte housekeeping protein; equal
amounts of protein were loaded. D, VEGF-A
transcripts per GAPDH transcript (n10) during
EHT culture. *P0.05 versus EHT day 0;
ANOVA followed by Bonferroni multiple com-
parison test.
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diameter: 24.70.4 m, length: 1141 m, volume: 57 102
1735 m3, n3 hearts, 80–100 cells each; Figure 6). Mean
diastolic sarcomere length was similar in all groups (EHT-
derived: 1.850.04 m [n31]; day-12 rat heart: 1.83
0.02 m [n28]; adult rat heart: 1.840.02 m, [n27]).
Organotypic Response of EHT to
Hypertrophic Stimuli
We cultured EHTs during the maturation phase (culture days
7–12) in the presence of phenylephrine (20 mol/L; PE) and
angiotensin II (100 nmol/L; Ang) to assess their responsive-
Figure 4. Molecular evidence for myocardial maturation in EHT. A, -Cardiac (cd) actin (n8–10/time point), and B, -skeletal (sk) actin
(n7–10/time point) transcripts per calsequestrin 2 (CSQ2) transcript in EHT and rat myocardium. C, -Sarcomeric actin protein con-
tent in EHT (indexed to CSQ2; n9–12/time point). D, -MHC (n9–10/time point), and E, -MHC (n7–10/time point) transcripts per
CSQ2 transcript in EHT and rat myocardium. F, -/-MHC transcript ratio in EHT and rat myocardium (n10/time point). Inset: repre-
sentative SYPRO Ruby–stained PAGE indicating -/-MHC protein composition in day 12 EHT. *P0.05 versus EHT day 0 (A, B, E,
and F) and EHT day 3 (C) or between indicated columns (in B, D, and F); ANOVA followed by Bonferroni multiple comparison test.
Figure 5. EHT proteome. A, Proteins were isolated from EHT (culture days 0 and 12) and separated by 2D electrophoresis using an
immobilized pH gradient strip (3–10 nonlinear); overlay of day 0 EHT (Cy3-labeled; green) and day 12 EHT (Cy5-labeled; red); overlay:
yellow. B, Abundance of ventricular MLC2 isoform (MLC2v) in day 0 and day 12 EHT (normalized to GAPDH and cardiomyocyte [CM]
number; n3/time-point). C, Abundance of vimentin in day 0 and day 12 EHT (normalized to GAPDH and nonmyocyte [NM] number;
n3/time point). *P0.05; 2-tailed unpaired Student t test.
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ness to simulated neurohumoral overstimulation. Compared
with standard medium conditions (EHT, day 12), we ob-
served a concentric hypertrophy at the cellular level with a
marked increase in cell width without major changes in cell
length (Figure 6). During the course of these experiments, we
also identified dramatic differences in responses to serum
(10% in the culture medium) with “hypertrophy-inducing
serum” (HIS), leading to a remarkable elongation of cardio-
myocytes without major changes in cell width (Figure 6).
These findings highlight the necessity for rigorous serum
screens but also indicate the opportunity to use EHT for
phenotypic screens to identify hypertrophy inducing secre-
tomes and/or specific hypertrophic factors. Importantly, the
phenotypic changes induced by PE/Ang and HIS were ac-
companied by distinct patterns of hypertrophic gene expres-
sion with particularly high ANP in HIS and low /-MHC
ratio as well as high -sk actin transcript abundance in
PE/Ang treated EHTs (Figure 7).
Figure 6. Hypertrophic cardiomyocyte growth in EHT and native heart. A, Length, B, mean width, and C, volume of EHT-derived cells
at culture day 0 (n60 cells) and day 12: (1) untreated (n113 cells), (2) simulated neurohumoral overstimulation with phenylephrine
(20 mol/L; PE) and angiotensin-2 (100 nmol/L; Ang; n111 cells), and (3) in the presence of hypertrophy-inducing serum (HIS; 10%;
n153 cells) during EHT culture days 7–12. Cell dimensions from postpartum day 12 (n3 hearts, 80–100 cells each) and adult (n3
hearts, 80–100 cells each) rat hearts are displayed for comparison. D, Immunostaining of cardiomyocytes from EHT culture days 0, 3,
and 12 (untreated, PE/Ang, and HIS) and rat myocardium. Red: -actinin, blue: DAPI-labeled nuclei; bar: 20 m. The image is an
assembly of individual photographs of representative cells from each group. *P0.05 versus day-12 native heart; §P0.05 versus EHT
day 0; ANOVA followed by Bonferroni multiple comparison test.
Figure 7. Fetal gene transcription program in
“hypertrophic” EHT. A, ANP transcripts per calse-
questrin 2 (CSQ2) transcript. B, -/-MHC tran-
script ratio. C, -skeletal (sk) actin transcripts per
CSQ2 transcript. D, -cardiac (cd) actin transcripts
per CSQ2 transcript. White bars: control EHTs;
black bars: EHTs stimulated with 20 mol/L phen-
ylephrine and 100 nmol/L angiotensin-2 during cul-
ture days 7–12; gray bars: EHTs stimulated with
HIS (10%) during culture days 7–12. Group size:
n7–10. *P0.05 versus control (Ctr); ANOVA fol-
lowed by Bonferroni multiple comparison test.
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Intense Matrix Restructuring During EHT Culture
At the time of casting, EHT contained 0.50.05 mg rat tail
collagen, 1.10.02 mg extracellular basement membrane
protein, 2.70.1 mg serum protein (in 210 L DMEM with
20% horse serum and 4% chick embryo extract), and a cell
suspension containing 2.20.1 mg proteins (2.5106 cells in
377 L DMEM with 10% fetal calf serum: cells, 0.5 mg;
serum, 1.7 mg; n4 in each group; Figure 8A). The nominal
EHT protein content decreased from 6.40.1 mg (n4) to
0.80.05 mg during culture (n4; Figure 8A) despite ele-
vated incorporation of 3H-phenylalanine (Online Figure III,
B), 3H-proline (Figure 8B), and 35S-methionine/cysteine
(Figure 8C). Experiments with the latter isotope mixture
demonstrated pronounced incorporation especially in 40-kDa
and200-kDa proteins probably resembling actin (molecular
weight: 43 kDa; see also Figure 4C) and myosin/collagen
(molecular weight: 220/290 kDa). High 3H-proline incorpo-
ration (Figure 8B) and high collagen type I/III transcript
levels (Figure 8D) at later stages of EHT culture provided
further evidence for endogenous ECM synthesis during the
EHT maturation phase (culture days 7–12). Sirius red staining
documented thick collagen fibers (orange in polarized light)
aligned along the major force axis in 12-day-old EHTs and
thin collagen fibers (green in polarized light), which represent
freshly synthesized collagen (Figure 8E). Additional evidence
for de novo collagen matrix production stems from transmis-
sion electron microcopy, which identified cross-striated ma-
ture collagen (Figure 8F), being absent in the original
collagen hydrogel. Cell loss (Figure 1A) and matrix disag-
gregation were apparently key factors for EHT protein loss,
especially during EHT consolidation (culture days 0–7).
Upregulation of matrix metalloproteinases (MMP-2 and
MMP-14; Online Figure VI, A and B) and their tissue
inhibitors (TIMP-1 and TIMP-2; Online Figure VI, C and D)
supported the hypothesis of intense matrix restructuring.
MMP-3 and MMP-13 could not be reliably detected in
Figure 8. Intense ECM restructuring during EHT
culture. A, Protein content of EHT at different time
points during culture. The day 0 column indicates
the contribution of collagen, culture medium ECM,
and cell suspension (contains 23% cell protein and
77% serum protein) fractions to total EHT protein
content at the time of casting. B, 3H-proline incor-
poration in EHTs during culture days 0 to 3, 3–7,
and 7–12 (n7–8). C, PAGE separation of proteins
from neonatal rat heart cells (Cells), collagen
(Coll.), ECM, horse serum (HS), chick embryo
extract (CEE), and EHT from culture days 0, 3, 7,
and 12. EHTs were labeled with 35S-cysteine/-
methionine on culture days 3, 7, and 12 (upper
left panel: Coomassie-stained PAGE; lower left
panel: autoradiography; right panel: superimposi-
tion of Coomassie-stained PAGE and correspond-
ing autoradiography; 25, 50, 75 g of pooled day
3, 7, and 12 EHT-protein were loaded as refer-
ence). D, Collagen type I (Coll-I) and collagen type
III (Coll-III) transcripts per GAPDH transcript in EHT
and rat myocardium (n8–10/time-point). E, Sirius
red staining of collagen fibers: thick collagen fibers
(orange); thin, newly synthesized collagen fibers
(green; highlighted in inset; bars: 10 m). F, Ultra-
structure of collagen fiber in day 12 EHT with
characteristic cross-striations; bar: 100 nm.
*P0.05 versus EHT day 3 (A), EHT days 0 to 3
(B), or EHT day 0 (D); ANOVA followed by Bonfer-
roni multiple comparison test.
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neonatal rat heart cells (Ct values: 40 [MMP-3] and 35
[MMP-13]; n10/target), but were clearly present at EHT-
culture day 3 (Ct values: 28 [MMP-3] and 25 [MMP-13];
n10/target), supporting the general concept of strong MMP-
based matrix remodeling, especially at early time points of
EHT culture.
Discussion
We investigated the hypothesis that immature rat cardiomyo-
cytes undergo terminal differentiation and a process of
advanced organotypic maturation in 3D EHT cultures and
made the following key observations: (1) cardiomyocytes
matured in EHT in a partially organotypic manner as indi-
cated by the formation of a clearly anisotropic and cross
striated rod-shaped cell morphology, abundant binucleation,
and a fetal-to-adult actin isoform shift; (2) the ventricular
MLC2 isoform was identified in EHT and strongly upregu-
lated on protein level, providing further evidence for ad-
vanced ventricular maturation; (3) cardiomyocytes in EHTs
responded to different hypertrophic stimuli with distinct
morphological (concentric versus eccentric hypertrophy) and
molecular (fetal gene expression) changes; (4) apoptosis in
enzymatically isolated myocytes limited cell and especially
cardiomyocyte survival in EHT; (5) EHT resembled nor-
moxic tissue at all investigated time points; (6) matrix
restructuring paralleled EHT-development and resulted in at
least partial replacement of ECM constituents. Collectively,
our data documents that the EHT culture format induces
terminal differentiation and advanced maturation of initially
immature cardiomyocytes to a “ventricle-like” phenotype in
vitro. The process of EHT “development” can be classified as
“EHT-consolidation” (culture days 0–7) followed by “EHT-
maturation” (culture days 7–12). Demonstration of qualita-
tively different responses, for example, concentric versus
eccentric hypertrophy, to distinct hypertrophic stimuli, for
example, PE/Ang versus HIS, suggests that EHT can be
exploited as a novel test-bed to dissect mechanisms of
hypertrophic growth.
Using tissue-engineered myocardium as a model of myo-
cardial development or in substance screening clearly de-
pends on its close resemblance with bona fide heart muscle.
Classical monolayer cultures display little structural, molec-
ular, and also functional similarities with mature myocardium
and do in general not respond reliably to hypertrophic stimuli,
unless subject to inherently hostile serum starvation at low
seeding density. Most notably, cardiomyocytes in monolayer
cultures quickly lose their regular rod-shaped morphology
and concomitantly reexpress fetal genes, indicating a molec-
ular “resetting” to a prenatal state of development.5–7 Growth
on patterned substrates may partially improve this condition
and support anisotropic growth19,20; yet, morphological and
molecular data documenting advanced maturation and forma-
tion of 3D tissue on a macroscopic scale are limited.
Particular morphological hallmarks of advanced cardio-
myocyte maturation are a rod-shaped geometry and binucle-
ation. Cardiomyocytes enzymatically isolated from EHTs
were rod-shaped and abundantly binucleated (37%), resem-
bling to some degree a state of maturity observed in cardio-
myocytes from 10- to 12-day-old rat hearts.2,21,22 However,
compared with heart-derived cardiomyocytes, EHT-derived
cardiomyocytes were thinner (length/width ratio, 12:1 in EHT
versus 7:1 in 12-day-old rat hearts and 5:1 in adult rat hearts).
This difference in aspect ratio was at least in part “normal-
ized” under PE and Ang stimulation (length/width ratio, 10:1;
Figure 6) but also paralleled by a “mild” induction of ANP,
all in the presence of “normal” serum. Interestingly, HIS
caused marked cardiomyocyte elongation and ANP upregu-
lation, responses which have been implicated in “pathologi-
cal” hypertrophy. Although additional studies are warranted
to establish phenotype “serome” relationships and identify
distinct underlying mechanisms, we believe that our data
provide compelling evidence for EHTs as a robust and nearly
“physiological” in vitro system, which could be used, for
example, to decipher the complex paracrine regulation of
physiological versus pathological growth. In line with this
notion, we could recently provide confirmatory evidence for
the role of the MEK1-ERK1/2 pathway in concentric versus
eccentric myocyte hypertrophy, conditions associated with
pressure and volume overload, respectively, by making use of
the EHT system.23
During physiological myocyte development, elongation of
cardiomyocytes precedes parallel sarcomere assembly.22,24
Subsequently, concentric hypertrophy, being the morpholog-
ical correlate of parallel sarcomeric assembly, represents a
compensatory mechanism to adapt to increasing load. Simi-
larly, multinucleation and polyploidy have been reported to
be enhanced under increasing load.25 Accordingly, DNA
synthesis (Figure 1D and 1E) was markedly elevated partic-
ularly after day 7 of EHT culture, that is, the time when EHTs
were subjected to phasic stretch. Interestingly, enhanced
DNA synthesis did not go along with an increase in myocyte
or nonmyocyte cell number, suggesting load-induced karyo-
kinesis, in the absence of palpable cytokinesis.
On the molecular level, the shift from skeletal to cardiac
actin transcript expression (Figure 4A and 4B and Online
Figure V) and the detection of elevated ventricular MLC2 in
12-day EHT (Figure 5B) provided further evidence for
advanced organotypic maturation of cardiomyocytes in EHT.
In apparent disagreement with this notion was the absence of
the commonly reported massive - to -MHC transcript
isoform shift. This may, however, be a consequence of the
low (subphysiologic) endogenous beating frequency of EHT
(2 Hz), making faster actin-myosin kinetics dispensable.
Whether electric stimulation of EHT at near physiological
frequencies (6 Hz) would facilitate a shift from the observed
7-fold -MHC transcript excess in spontaneously beating
EHTs to a 88-fold excess as observed in adult heart muscle
(Figure 4F), needs further investigation. Interestingly, PE/
Ang and HIS lowered the -/-MHC transcript ratio, as
anticipated under hypertrophy-inducing conditions.
Abundant caspase-3 activation and elevated bax expression
suggested that apoptosis limited cell survival in EHT. It is
important to note that caspase activation does not always lead
to fully executed apoptosis with nuclear fragmentation but is
also involved in reversible myofilament breakdown after cell
isolation.26 Induction of apoptosis during enzymatic cell
isolation and cell loss during early culture are also commonly
observed in monolayer cardiomyocyte cultures (Online Fig-
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ure IV). This set of data collectively argues against the notion
that the reported apoptosis represents a specific tissue engi-
neering limitation. We could recently demonstrate that acti-
vation of prosurvival pathways such as the Akt pathway can
protect cardiomyocytes in early EHT cultures from
apoptosis.27
Hypoxia-induced apoptosis has been suggested as a
main limitation for cell survival in tissue-engineered myo-
cardium,28 and we initially interpreted VEGF-A transcript
elevation as a sign of chronic hypoxia in particular in later
stages of EHT culture. However, more comprehensive inves-
tigations of more sensitive biomarkers for acute (HIF-1) and
chronic (PHD2/3) hypoxia did not provide any evidence in
support of EHT hypoxia during culture. We emphasize that
cardiomyocytes are physiologically exposed to oxygen pres-
sure below 40 mm Hg, which corresponds to 5% ambient
oxygen,29 and that the provided oxygen supply (21% ambient
oxygen) is apparently sufficient for normoxic EHT mainte-
nance. Although the stimulus for enhanced VEGF-A expres-
sion has not been identified, one should consider that
VEGF-A by itself may be cardioprotective30 and in fact may
be an important prerequisite for the observed rapid vascular-
ization of EHT grafts in vivo.31,32
Of particular interest for in vivo applications in regenera-
tive medicine is also the apparent replacement of the original
hydrogel by endogenously produced ECM. This remodeling
process is on the one hand crucial for the formation of
mechanically stable EHTs. On the other hand, it provides a
perspective for the generation of nonimmunogenic “therapeu-
tic” EHTs from autologous cells.
Taken together, cardiomyocyte maturation in EHT com-
pares favorably to myocyte maturation in monolayer culture
and does to some extent simulate physiological development
in vivo. The observed differences in cardiomyocyte size and
MHC isoform composition may be a consequence of “sub-
physiologic” loading and low intrinsic contraction frequency
and thus may be interpreted as a “physiological” response to
partially unphysiologic culture conditions. Interestingly, con-
centric and eccentric hypertrophic growth could be stimulated
in EHT using simulated neurohumoral/serum activation.
These data in particular suggest that EHT may constitute a
unique model system to study mechanisms governing hyper-
trophic growth in cardiomyocytes. As a consequence of the
observed differentiation and maturation inducing capacity,
EHT cultures may also find a novel application as in vitro
test-bed to define the fate of progenitor cells in a tissue-like
context.
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Novelty and Significance
What Is Known?
● Tissue-engineered myocardium may be used as in vitro tool for drug
development and as a surrogate for heart muscle for in vivo
applications in myocardial repair.
● Cardiac myocytes dedifferentiate in culture, leading to a loss in
organotypic cell morphology and reexpression of fetal genes.
● The validity of classical monolayer cultures as in vitro platform for
modeling of hypertrophic cardiomyocyte growth is limited.
What New Information Does This Article Contribute?
● Engineered heart tissue (EHT) formation is a staged process com-
prising an early tissue consolidation phase with selection of the
“fittest” myocytes and fibroblasts as well as comprehensive
extracellular matrix (ECM) remodeling; this is followed by a phase
of organotypic maturation.
● Organotypic maturation of cardiomyocytes in EHT includes terminal
differentiation, abundant binucleation, development of an essen-
tially rod-shaped morphology, and a fetal-to-adult shift in gene
expression pattern.
● EHT may be useful in modeling of concentric versus eccentric
cardiomyocyte hypertrophy.
Tissue engineering could potentially provide realistic heart
muscle models and surrogate myocardium. However, cellular
maturity in tissue-engineered myocardium has been sparsely
documented. We show that a unique collagen hydrogel-based,
cardiac tissue-engineering format, EHT, supports organotypic
maturation in originally immature cardiomyocytes from neonatal
rats. Our studies provide novel insight into the developmental
properties of EHT, for example, hypertrophic growth under
normoxic conditions and comprehensive ECM remodeling lead-
ing to replacement of the original hydrogel scaffold with ECM.
The latter finding highlights the predicted but thus far unde-
monstrated capacity of the cardiac fibroblast to function as a key
“engineer” in myocardial tissue engineering. We have estab-
lished appropriate experimental conditions that differentially
affect cardiomyocyte growth (ie, concentric hypertrophy under
simulated neurohumoral activation and eccentric hypertrophy in
the presence of hypertrophy-inducing serum). Collectively, the
results of this study enhance the utility of the EHT technology as
methodological bridge between classic 2D cell culture and
animal models. It may represent a useful tool for identifying
specific environmental cues that facilitate organotypic matura-
tion of cardiomyocytes from human (stem) cell sources as well.
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Correction
Terminal Differentiation, Advanced Organotypic Maturation, and Modeling of Hypertrophic
Growth in Engineered Heart Tissue: Correction
In the article that appears on page 1105 of the October 28, 2011 issue, an author’s name is
misspelled. The name should have appeared as Doerthe M. Katschinski.
The error has been noted and corrected in the online version of the article, which is available
at http://circres.ahajournals.org/content/109/10/1105.full.
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EXPANDED MATERIALS AND METHODS 
Experimental animals were maintained in accordance with the guiding principles of the American 
Physiological Society.  Animal experiments were approved by the local authorities (Regierung von 
Mittelfranken: 621.2531.31-2/00 and -17/01; BWG of the Freie und Hansestadt Hamburg; 
Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit). 
 
EHT construction and treatment.  Heart cells were isolated from neonatal rats (postnatal days 1-3) 
using a fractionated DNase/Trypsin digestion protocol without preplating to maintain the original 
cardiomyocyte:non-myocyte composition1, 2.  EHTs (reconstitution volume: 0.9 ml) were prepared by 
pipetting a mixture containing the isolated heart cells (2.5x106 cells in DMEM with 10% fetal calf 
serum, 1 mmol/l glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin), pH-neutralized 
collagen type I from rat tails (0.5 mg/EHT – measured by the Sircol Collagen Assay; Biocolor), 
basement membrane protein containing Engelbreth-Holm-Swarm tumor exudate (10% v/v; BD 
Biosciences), and concentrated serum-containing culture medium (2xDMEM, 20% horse serum, 4% 
chick embryo extract, 200 U/ml penicillin, and 200 µg/ml streptomycin) in circular molds (inner 
diameter, 8 mm; outer diameter, 16 mm; height, 5 mm3).  Spontaneously beating EHTs were 
transferred to stretch devices on culture day 7 to continue culture under phasic load (from 100 to 110% 
of slack length at 2 Hz) for additional 5 days.  EHTs were treated with 20 µmol/L phenylephrine and 
100 nmol/L angiotensin-II from day 7-12 with daily medium change to induce hypertrophy.  For 2D 
culture experiments neonatal heart cells were seeded in 6-well plates (5x105/well) coated with the 
EHT matrix (diluted 1:50 in PBS) and cultured in parallel to EHTs in standard primary cardiomyocyte 
culture medium (DMEM, 10% fetal calf serum, 100 µmol/L 5-bromo-2'-deoxyuridine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin). 
 
3H-thymidine incorporation.  EHTs were maintained in standard culture medium with 1 µCi/ml 3H-
thymidine for 6 hours on the indicated culture days.  After washing in ice cold PBS, EHTs were 
dissolved in ice cold lysis buffer (10 mmol/L trishydroxylaminomethane [Tris; pH 8], 1 mmol/L 
ethylene-diamine-tetraacetic acid [EDTA; pH 8], 0.1% sodium dodecyl sulfate [SDS]) followed by 6 h 
proteinase K (0.1 µg/µl) digestion at 55 °C.  DNA was precipitated in isopropanol after DNase-free 
RNase treatment (0.02 µg/µl for 60 min at 37 °C) and protein extraction in potassium acetate solution 
(3 mol/L potassium/5 mol/L acetate).  After washing in 70% ethanol, DNA was resuspended in 
Tris/EDTA-buffer (100 mmol/L Tris, 10 mmol/L EDTA; pH 7.6).  DNA content was measured by 
spectrophotometry and 3H-activity was assessed by liquid scintillation counting. 
 
Cell isolation from EHT.  EHTs were immersed in modified Bicarbonate-Free Hanks’ Balanced Salt 
Solution with HEPES (BFHH; NaCl 136.9 mmol/L, KCl 5.36 mmol/L, MgSO4 0.81 mmol/L, glucose 
5.55 mmol/L, CaCl2 0.0125 mmol/L, KH2PO4 0.44 mmol/L, Na2HPO4 0.34 mmol/L, HEPES 20 
mmol/L) containing 0.035 mg/ml Liberase Blendzyme III (Roche) and 30 mmol/L BDM (2,3-
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butanedione monoxime) at 37 °C for 60 min.  Enzymatic activity was stopped by addition of 10% 
FBS, 5 mmol/L EDTA.  Isolated cells were fixed for immunostaining or flow cytometry as described 
below. 
 
Histology.  EHTs or dispersed single cells were fixed in neutral buffered 4% formaldehyde/1% 
methanol, pH 7.4 with 30 mmol/L BDM and subjected either to light (LM) or confocal laser scanning 
(CLSM; Zeiss 510 Meta or 710/NLO LSM) microscopy, as described recently 3.  Cryo-sections (10 
µm; Leica CM3050 S) were stained with phalloidin-Alexa 488 (3.3 U/ml; Molecular Probes) to label 
f-actin, DAPI (4',6-diamidino-2-phenylindole; 1 µg/ml) to label nuclei, and antibodies directed against 
α-actinin (1:1000; Sigma), and activated caspase-3 (1:250; Promega) with appropriate secondary 
antibodies.  For Sirius red staining EHTs were embedded in paraffin, and sectioned at a thickness of 6 
µm.  After de-waxing in Roti-Histol (Roth) for 2x 15 min, the sections were hydrated through a 
decreasing ethanol series and washed with distilled water for 2x 5 min.  Sections were incubated for 
60 min in a solution of 0.5 g Sirius red F3B (C.I. 35782) in 500 ml of saturated aqueous solution of 
picric acid, briefly washed in acidified water (5 ml glacial acetic acid per liter of distilled water), 
dehydrated and mounted in Histokitt.  Sections were then subjected to polarized light microscopy 
(Olympus BX41).  Green and red channels were separated by setting a threshold in the green-red 
distribution using the CIE lab function of ImageJ.  Respective images of above and below threshold 
signals as well as merged image were computed applying identical settings.  For transmission electron 
microscopy (TEM) EHTs were fixed in 2.5% glutaraldehyde (in PBS with 1 mmol/L CaCl2 and 30 
mmol/L BDM) overnight at 4°C.  After extensive washing in PBS, EHTs were postfixed for 2 h in 
osmiumtetroxyd/PBS (1:1).  After epon embedding, ultrathin sections (50 nm) were cut (Ultracut 
UCT, Leica), contrasted with uranyl acetate and lead citrate, and imaged with a Zeiss Leo 906 EM. 
 
Flow cytometry.  Dispersed cells from neonatal rat (P0-3) and EHTs at different time-points were 
fixed in ice-cold 70% ethanol.  Staining for α-actinin (Sigma) or vimentin (Abcam) was performed in 
the presence of 0.5% Triton-X at 4°C for 45 min.  Appropriate secondary antibodies were applied for 
30 min at room temperature.  Negative controls were incubated with the secondary antibody alone.  
DNA was stained with DAPI (1 µg/ml).  Samples were run on a LSRII cytometer and analysed with 
FacsDiva software (BD Biosciences).  The gating strategy to exclude cell clumps and multinucleated 
cells was based on the width of the DAPI signal.  DNA content/cell cycle was analyzed using ModFit 
LT 3.2 software (Verity). 
 
Cell isolation from native heart.  After an intra-peritoneal bolus injection of heparin (500 IU) 12 day 
and 12 week old Wistar rats were euthanized.  Hearts were quickly excised and cells were isolated 
using a modified Langendorff method4.  Briefly, hearts were digested with 0.1 mg/ml Liberase 
Blendzyme III (Roche) in oxygenized perfusion buffer (NaCl 113 mmol/L, KCl 4.7 mmol/L, KH2PO4 
0.6 mmol/L, Na2HPO4 0.6 mmol/L, MgSO4 1.2 mmol/L, NaHCO3 12 mmol/L, KHCO3 10 mmol/L, 
HEPES 10 mmol/L, taurine 30 mmol/L, glucose 5.55 mmol/L, BDM 10 mmol/L, calcium 0.0125 
mmol/L).  Single cells were fixed for immunostaining as described above.  
 
RNA/DNA isolation and quantitative RT-PCR (qPCR).  RNA and DNA were isolated using the 
Trizol®-method (Invitrogen) and quantified by spectrophotometry.  cDNA was prepared from 2 µg 
total RNA by reverse transcription with MMLV-RT (Invitrogen) utilizing random hexamere primers 
(Roche) following standard protocols (Invitrogen).  qPCR was performed in a 384 well format ABI 
prism HT 7900 system (Applied Biosystems) using gene-specific primers and fluorogenic probes (5’ 
FAM and 3’ TAMRA; Online Table II) as described earlier5, unless indicated otherwise (see below).  
The reaction mixture contained 20 ng input cDNA, 3 mmol/l MgCl2, 0.4 µmol/l forward and reverse 
primer, 0.5 µmol/l probe, 0.8 mmol/l NTP (Applied Biosystems), and 0.05 U TaqGold polymerase 
(Applied Biosystems) in a total volume of 10 µl supplemented with TaqPolymerase buffer II (Applied 
Biosystems).  We used following temperature protocol: 30 sec at 50 °C and 10 min at 95 °C followed 
by 45 cycles of 30 sec at 95 °C and 1 min at 58 °C.  GAPDH expression was similar in all study 
groups and was therefore employed to normalize for differences in RNA quantity and RT-efficiency.  
Cardiomyocyte-specific transcript quantity was indexed to the expression of muscle specific 
calsequestrin 2 (CSQ2).  The linearity of each PCR was confirmed by analyzing serial cDNA 
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dilutions, prepared from total RNA isolated from neonatal rat hearts.  Quantification of transcripts was 
performed using the Standard Curve algorithm6. PHD2 and PHD3 mRNA levels were quantified using 
1 μl of cDNA (Fermentas) and a SYBR Green qPCR reaction kit (Clontech) in combination with a 
MX3000P light cycler (Stratagene) as described before7.  The initial template concentration of each 
sample was calculated by comparison with serial dilutions of a calibrated standard.  Primer sequences: 
PHD2 forward TACAGGATAAACGGCCGACAC and PHD2 reverse 
GGCTTGAGTTCAACCCTCAC; PHD3 forward GTTAACCCGAGACTGGACGA and PHD3 
reverse CATACCGCTAGGCTTTGCTC. 
 
Development of a cardiomyocyte specific qPCR assay.  To better account for cardiomyocyte loss 
we developed a PCR-assay allowing the quantification of 17,500-1,750,000 cardiomyocytes in a 
mixed heart cell population, based on the detection of muscle specific calsequestrin 2 (CSQ2) 
transcripts (Online Figure VII).  We designed intron-spanning fluorogenic TaqMan probes (5’ FAM, 
3’ TAMRA) and adjacent primer pairs to amplify muscle specific CSQ2, GAPDH, and 18S-RNA.  Rat 
heart cells were isolated as described and cardiomyocytes were enriched by preplating, resulting in a 
cell suspension containing 70% cardiomyocytes as identified by α–sarcomeric actinin labeling2.  
Subsequently, heart cells were mixed with defined numbers of cardiac non-myocytes.  Non-myocytes 
were prepared by propagating a quickly adhering cell fraction from the original neonatal rat heart cell 
isolate.  This cell fraction was grown to subconfluency (70%), trypsinized, frozen in 7.5% DMSO-
containing cell culture medium, thawed, and re-grown.  This procedure was repeated at least twice, 
yielding heart cell cultures free of beating or non-beating cardiomyocytes.  Cell mixtures were 
subjected to RNA isolation (Trizol®, Invitrogen).  Reverse transcription and qPCR were performed as 
described with different quantities of input cDNA (20 pg and 20 ng) to demonstrate that 
cardiomyocytes express constant levels of CSQ2 transcripts.  This was further confirmed with two 
different CSQ2 primer-probe sets (see below).  Similar cDNA loading was confirmed by GAPDH and 
18S-RNA transcript analyses: 
 
CSQ2:  NCBI accession#: AF001334       
Forward: TTT CTG ACG GAG ACG TTC AGG     
Probe:  TGG CTG CCT ACA GTA CGC TGG GAA C    
Reverse: TAG CAG GAC AGA GAG GGT GCA     
 
CSQ2:  Ensemble accession#: ENSRNOG00000016243 
Forward: CCA AGA GGC TGG GCT TCA G      
Probe:  CGA TCT CTA CTG GGT CCT CAA TGA GGT CCA A   
Reverse: CCT CAT TCT TGA AAA AGC CAA GC     
 
GAPDH:  NCBI accession#: NC005103 
Forward: AAC TCC CTC AAG ATT GTC AGC AA     
Probe:  ATG GAC TGT GGT CAT GAG CCC TTC CA    
Reverse: CAG TCT TCT GAG TGG CAG TGA TG     
 
18S-RNA:  NCBI accession#: V01270 
Forward: ACG ACC CAT TCG AAC GTC      
Probe:  CCT ATC AAC TTT CGA TGG TAG TCG CCG T   
Reverse: CTT GGA TGT GGT AGC CGT TT   
 
Immunoblotting.  EHTs were washed thoroughly in ice cold PBS and rapidly homogenized in lysis 
buffer containing 30 mmol/L Tris (pH 8.8), 5 mmol/L EDTA (pH 8), 3% SDS, 10% glycerol, 30 
mmol/L NaF, and 2 μg/ml aprotinin or 4 mmol/L urea, 140 mmol/L Tris (pH 6.8), 1% SDS, 2% 
Nonidet P-40, and protease inhibitors (Roche Applied Science).  After centrifugation at 13,000 g for 
10 min, supernatants containing soluble proteins were subjected to protein concentration measurement 
using modified Lowry or Bradford methods, respectively.  Equal amounts of protein (30-100 µg) were 
resolved by SDS-PAGE and transferred onto polyvinylidene fluoride (sarcomeric actin) or 
nitrocellulose (HIF-1α, calsequestrin) membranes by semidry blotting.  Primary antibodies used were: 
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anti-sarcomeric actin (clone 5C5; Sigma), anti-HIF-1α (Novus, NB100-479), anti-calsequestrin 2 
(AffinitiBioReagents).  Primary antibodies were detected with appropriate horseradish peroxidase 
coupled secondary antibodies.  Sarcomeric actin immunocomplexes were enhanced with the ECL-plus 
kit (Amersham Biosciences) and recorded with a ChemiDoc system (Syngene).  Signals were 
quantified with Gene-Tools software (Syngene).  For detection of HIF-1α membranes were incubated 
with 100 mmol/L Tris-HCl (pH 8.5), 2.65 mmol/L H2O2, 0.45 mmol/L luminol, and 0.625 mmol/L 
coumaric acid for 1 min.  Chemiluminescence signals were detected with the LAS-3000 Image Reader 
(Fujifilm).  
 
Detection of myosin heavy chain isoforms.  To assess myosin heavy chain isoform composition 
EHTs were homogenized in sample buffer containing 50 mmol/L Tris-HCl (pH 6.8), 5 mmol/L 
EDTA, 10% glycerol, 8 µg/ml leupeptin, 1% beta-mercaptoethanol, 20% SDS, 0.1% (w/v) 
dithiothreitol, 6 µmol/L bromophenol blue, and washing buffer (5 mmol/L Tris-EDTA, pH 8.0).  The 
separating gel contained 7.5% total acrylamide (acrylamide to bis-acrylamide ratio, 30:0.8), the 
stacking gel contained 4% total acrylamide.  To check for linearity, different amounts of EHT (0.5–3.0 
µg) were loaded and the densities of the myosin heavy chain bands were analyzed; a load of 1.5 µg per 
lane was selected as it was found to be within the linear range.  After separation of proteins, gels were 
stained overnight with SYPRO Ruby (Molecular Probes).  Fixation and washing were performed 
according to the manufacturer’s guidelines.  Gels were digitized using LAS-4000 Image Reader 
(Fujifilm; 460 nm/605 nm Ex/Em) and signals were analyzed using Multi Gauge software (Fujifilm).  
 
2D electrophoresis (2-DE).  EHT samples were homogenized in 9 mol/L urea, 1% DTT, 4% 
CHAPS, protease and phosphatase inhibitors (Complete Mini, Roche), and 0.8% Pharmalytes 
3-10.  For difference in-gel electrophoresis (DIGE), proteins were precipitated (ReadyPrep 2D 
Clean-up kit, Biorad) and re-suspended using a lysis buffer (30 mmol/L TrisCl pH 8.5, 8 mol/L 
urea, 4% w/v CHAPS) compatible with DIGE labelling (GE healthcare).  After centrifugation at 
13,000 g for 10 min, the supernatant containing soluble proteins was harvested and the protein 
concentration was determined using a modification of the method described by Bradford.  The 
fluorescence dye labelling reaction was carried out at a dye/protein ratio of 200 pmol/L / 50 μg.  After 
incubation on ice for 30 min, the labelling reaction was stopped by scavenging non-bound dyes with 
10 mmol/L lysine (L8662, Sigma) for 15 min.  Protein extracts (50 µg/sample) were loaded on 
nonlinear immobilized pH gradient (IPG) 18-cm strips, pH 3-10 (GE Healthcare) using an in-gel 
rehydration method.  Loaded IPG-strips were rehydrated in 8 mol/L urea, 0.5% w/v CHAPS, 0.2% 
w/v DTT, and 0.2 % w/v Pharmalyte pH 3-10 overnight in a reswelling tray.  Strips were 
isoelectrically focused at 0.05 mA/IPG-strip and 35 kVh at 20 °C (IPGphor, GE healthcare) and 
subsequently equilibrated in 6 mol/L urea containing 30% v/v glycerol, 2% w/v SDS, and 0.01% w/v 
bromphenol blue, with addition of 1% w/v DTT for 15 min, followed by the same buffer without DTT, 
but with the addition of 4.8% w/v iodoacetamide for 15 min.  Large-format gradient gels (5-10% 
stack, 10-16% linear, 16-20% stack) were cast using a 2-DE optimizer (NextGen Sciences, 
Huntingdon, UK).  Gels were subsequently overlaid with water-saturated butanol (2:3) and left to 
polymerize overnight.  SDS-PAGE was performed using the Ettan DaltSix system (GE healthcare).  
After electrophoresis, fluorescence images were acquired by using the Ettan DIGE Imager (GE 
Healthcare) with the following parameters: exposure time: Cy2, 0.8 sec, Cy3, 0.3 sec, Cy5, 0.5 sec, 
pixel size: 0.1 mm.  Images were analyzed by DeCyder software (version 7.0, GE Healthcare).  The 2-
DE gels were fixed overnight in methanol:acetic acid:water solution (4:1:5 v/v/v) and visualized by 
silver staining using the Plus one silver staining kit (GE healthcare) without glutaraldehyde to ensure 
compatibility with subsequent mass spectrometry analysis.  Silver-stained gels were scanned in 
transmission scan mode using a calibrated scanner (GS-800, Biorad). 
 
Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS).  Gel pieces 
containing selected protein spots were treated overnight with modified trypsin (Promega) according to 
a published protocol modified for use with an Investigator ProGest (Genomic Solutions) robotic 
digestion system8.  Following enzymatic degradation, peptides were separated by a nanoflow HPLC 
system on a reverse-phase column (Acclaim PepMap100, C18, 25cm, 5µm, 100Å, Dionex) and 
applied to a LTQ ion-trap mass spectrometer (Thermo Fisher Scientific) with electron transfer 
 at Vrije Universiteit--Amsterdam on April 3, 2012http://circres.ahajournals.org/Downloaded from 
#CIRCRESAHA/2011/251843/R1 
 
 5 
dissociation (ETD).  Spectra were collected from the ion-trap mass analyzer using full ion scan mode 
over the mass-to-charge (m/z) range 450-2000.  MS-MS scans were performed on each ion using 
dynamic exclusion and alternating collision-induced dissociation (CID) and ETD.  Database search 
was performed using the SEQUEST (Thermo Fisher Scientific) and X! Tandem software.  Two 
missed cleavages per peptide were allowed and carbamidomethylation of cysteine as well as partial 
oxidation of methionine were assumed.  Peptide identifications were accepted if they could be 
established at greater than 95% probability as specified by the Peptide Prophet algorithm.  Protein 
identifications were accepted if they could be established at greater than 99% probability with at least 
two independent peptides. 
 
3H-phenylalanine and 3H-proline incorporation.  EHTs were maintained in standard culture 
medium with 1 µCi/ml 3H-phenylalanine or 3H-proline as indicated.  Protein was precipitated in 10% 
ice-cold trichloroacetic acid (TCA) at 4 °C over night.  The supernatant was collected and subjected to 
liquid scintillation counting to assess the non-incorporated fraction of the isotopes.  The protein 
precipitate was washed twice in ice-cold PBS, suspended in 1 mmol/L NaOH containing 0.01% SDS 
for 2 h at 37 °C, and subjected to liquid scintillation counting.  Total protein content was analyzed by a 
modified Lowry-Assay (Bio-Rad DC Protein Assay). 
 
35S-cysteine/-methionine incorporation, PAGE, and autoradiography.  EHTs were cultured in 
cysteine- and methionine-free EHT culture medium with 4.5 g/l glucose for 6 h and subsequently 
incubated for 18 h in fresh cysteine- and methionine-free EHT culture medium supplemented with 100 
µCi/ml 35S-cysteine/-methionine on the indicated culture days.  EHT protein was prepared and 
quantified as described above.  Similar quantities of total proteins were loaded on 7% SDS-
polyacrylamide gels and separated electrophoretically.  Gels were stained with Coomassie blue, 
immersed in Amplify Fluorographic solution (Amersham Biosciences), vacuum dried, and subjected 
to autoradiography on intensifier screens (Expo Hyperfilm; Amersham Biosciences) for 6.5 h at -80 
°C. 
 
Statistical analyses.  Data are presented as mean ± standard error of the mean (SEM).  Statistical 
differences were determined using two-sided, unpaired Student’s t-tests or one-way analysis of 
variance (ANOVA) followed by Bonferroni’s multiple comparison test.  A P value < 0.05 was 
considered statistically significant. 
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ONLINE FIGURE/TABLE/VIDEO LEGENDS 
 
Online Table I.  Protein identifications by tandem mass spectrometry (LC-MS/MS). The amino 
acid sequences and scores of the identified peptides are provided. The blue color highlights the 
number of unique peptides, unique spectra, total spectra, and the sequence coverage as obtained by 
CID.  The corresponding values for ETD (if applicable) are given below, but are not highlighted. 
 
Online Table II.  qPCR primers and probes. 
 
Online Figure I.  Quantification of cardiomyocytes and fibroblasts during EHT culture by flow 
cytometry.  Representative plots identify distinct α-actinin- (A) and vimentin-positive cell 
populations (B) at the indicated days of EHT culture.  Panels resemble overlays of individual dot 
plots: in red cell pools labeled for actinin (A) or vimentin (B); in grey cell pools exposed to secondary 
antibody only. 
 
Online Figure II.  DNA content in mononucleated cardiomyocytes and non-myocytes during 
EHT culture assessed by flow cytometry.  A, Representative plots of DNA content in 
mononucleated cardiomyocytes (actinin-positive, red) and non-myocytes (actinin-negative, dark grey) 
at day 0 and day 12 of EHT culture.  B, Fractions of mononucleated cardiomyocyte (top panel) and 
non-myocyte (lower panel) populations at day 0 (n=6) and day 12 (n=4) of EHT culture with 2N, 4N, 
and 8N DNA content.   
 
Online Figure III.  Surrogate parameters suggesting hypertrophic growth in EHTs.  A, 
RNA/DNA ratio in EHTs on culture days 0 (n=18), 3 (n=19), 7 (n=10), and 12 (n=16).  B, 3H-
phenylalanine incorporation during EHT culture days 0-3 (n=7), 3-7 (n=8), and 7-12 (n=5).  *P< 0.05 
vs. EHT day 0 (A) and EHT days 0-3 (B); ANOVA and Bonferroni’s multiple comparison test. 
 
Online Figure IV.  Cell death in EHT and monolayer (2D) culture.  A, Analysis of DNA content in 
EHT- and 2D culture-derived cells (n=3 each).  Sub-G1 fraction (green) denotes dead/apoptotic cells 
with condensed nuclei.  B, Trypan-blue exclusion in EHT- and 2D culture-derived cells at culture day 
1 (n=5 [EHT], n=4 [2D]). C, Comparison of CSQ2 transcript abundance in EHT (black bars) vs. 2D 
culture (white bars), n=5-6/time-point.  *P<0.05 vs. day 0 (grey bar); ANOVA and Bonferroni’s 
multiple comparison test. 
 
Online Figure V.  Molecular markers of maturation in monolayer (2D) vs. EHT culture.  A, ANP 
transcripts per GAPDH transcript; B, skeletal actin transcripts per GAPDH transcript; C, cardiac actin 
transcripts per GAPDH transcript in isolated neonatal heart cells at day 0 (black bars; n=5), 2D 
cultured cells at day 12 (blue bars; n=6), and EHT at day 12 (green bars; n=5).  D, Correlation of 
cardiac and skeletal actin transcript abundance in freshly isolated neonatal heart cells (d0; black), in 
2D culture (culture days 3,7, and 12 [left panel]) and EHT culture (culture days 3, 7, and 12 [middle 
panel]) - black arrows denote the trend in expression pattern change in 2D and EHT culture; right 
panel:  direct comparison of 12 day 2D vs. EHT cultures and neonatal cardiomyocytes.  *P<0.05 2D 
vs. EHT; Student’s t-test. 
 
Online Figue VI.  ECM restructuring during EHT development.  A, matrix metalloprotease-2 
(MMP-2; n=8-10); B, MMP-14 (n=7-10); tissue inhibitor of matrix metalloprotease-1 (C, TIMP-1; 
n=7-10), and TIMP-2 (D; n=7-10) transcripts per GAPDH transcript in EHT and native rat heart 
tissue.  *P<0.05 vs. EHT day 0; ANOVA followed by Bonferroni’s multiple comparison test.  
 at Vrije Universiteit--Amsterdam on April 3, 2012http://circres.ahajournals.org/Downloaded from 
#CIRCRESAHA/2011/251843/R1 
 
 7 
 
Online Figure VII.  Development of a cardiomyocyte-specific qPCR assay to allow 
approximation of cardiomyocyte content in mixed cell populations.  Detection of CSQ2 (NCBI 
accession#: AF001334; squares) and GAPDH (NCBI accession#: NC005103; circles) transcripts in 
2.5x106 cells containing the indicated cardiomyocyte fraction by qPCR.  High Ct-values indicate low 
transcript abundance.  Symbols indicate individual Ct-values.  Bars indicate the respective means.  A 
Ct-value difference of 3.3 ideally represents a 10-fold difference in transcript abundance.  Similar data 
could be obtained using alternative primer-probe pairs for muscle specific CSQ2 (Ensemble 
accession#: ENSRNOG00000016243) or 18S-RNA (NCBI accession#: V01270). 
 
 
Online Video I: Spontaneous contractions in EHTs on culture day 3. 
Online Video II: Spontaneous contractions of EHTs on culture day 7. 
Online Video III: Spontaneous contractions of EHTs on culture day 12. 
Online Video IV: Animated 3D reconstruction of adjacent optical sections from EHTs on 
culture days 0, 3, 7, and 12.  
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Digestion Enzyme: Trypsin
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Search Engine: X! Tandem
Fragment Tolerance: 1.00 Da (Monoisotopic)
Parent Tolerance: 2.0 Da (Monoisotopic)
Fixed Modifications: +57 on C (Carbamidomethyl)
Variable Modifications: +16 on M (Oxidation)
Database: a subset of the uniprot_sprot database
Digestion Enzyme: Trypsin
Max Missed Cleavages: 2
Scaffold Version: Scaffold-01_06_19
Peptide Thresholds: 95.0% minimum 
Protein Thresholds: 99.0% minimum and 2 peptides minimum
Protein name Protein accession numbers Protein molecular weight Protein identificatioNumber of un Number of un Number of totPercentage of Percentage sePeptide sequence Previous aminNext amino acBest Peptide i Best SEQUESTBest SEQUESTBest X! TandeNumber of ideNumber of ideNumber of ideNumber of ideNumber of en Calculated PepPeptide start i Peptide stop index
Nidogen-1 precursor (Entactin) - Mus musculus (Mouse) NID1_MOUSE 136603,6 100,00% 4 5 5 0,21% 4,10% ASLHGGEPTTIIR R Q 95,00% 2,61 0,356 -0,146 0 1 1 0 2 1351,7336 1003 1015
QTITFQECAHDDAR R P 95,00% 3,01 0,233 0 0 1 0 0 2 1691,745 609 622
TNSVIAMDLAISK K E 95,00% 2,82 0,274 -0,699 0 1 0 0 2 1378,7252 1168 1180
VLFDTGLVNPR R G 95,00% 2,73 0,0978 1,96 0 1 0 0 2 1230,6848 1055 1065
99,80% 2 2 2 0,08% 2,17% ASLHGGEPTTIIR R Q 95,00% 4,08 0,322 0 0 0 1 0 2 1351,7336 1003 1015
QTITFQECAHDDAR R P 95,00% 2,97 0,152 0 0 1 0 0 2 1691,745 609 622
Collagen alpha-1(I) chain precursor (Alpha-1 type I collagen) - Mus musculus (MouseCO1A1_MOUSE 138014,7 100,00% 2 2 2 0,09% 2,00% DRDLEVDTTLK R S 95,00% 2,56 0,38 -1,04 0 1 0 0 2 1304,6702 1215 1225
GETGPAGPAGPIGPAGAR R G 95,00% 2,96 0,446 0,553 0 1 0 0 2 1532,7826 1056 1073
Vinculin (Metavinculin) - Mus musculus (Mouse) VINC_MOUSE 116701,4 100,00% 9 9 9 0,36% 10,60% AGEVINQPMMMAAR K Q 95,00% 2,9 0,184 0,0506 0 1 0 0 2 1566,7079 890 903
ALASQLQDSLK R D 95,00% 3,06 0,377 2,33 0 1 0 0 2 1173,6481 571 581
DPNASPGDAGEQAIR R Q 95,00% 2,9 0,297 -0,301 0 1 0 0 2 1497,6936 286 300
LLAVAATAPPDAPNR K E 95,00% 2,11 0,27 -0,699 0 1 0 0 2 1476,8176 608 622
MLGQMTDQVADLR K A 95,00% 3,1 0,391 0 0 1 0 0 2 1509,7043 327 339
MSAEINEIIR K V 95,00% 2,05 0,146 1,72 0 1 0 0 2 1191,6044 237 246
MTGLVDEAIDTK K S 95,00% 2,85 0,268 0 0 1 0 0 2 1308,636 709 720
QVATALQNLQTK K T 95,00% 2,69 0,348 0,337 0 1 0 0 2 1314,7383 465 476
VMLVNSMNTVK R E 95,00% 2,77 0,231 1,89 0 1 0 0 2 1267,6388 189 199
100,00% 3 3 3 0,12% 3,57% ALASQLQDSLK R D 95,00% 3,02 0,24 0 0 1 0 0 2 1173,6481 571 581
LLAVAATAPPDAPNR K E 95,00% 2,7 0,279 0 0 1 0 0 2 1476,8176 608 622
QVATALQNLQTK K T 95,00% 3,22 0,196 0 0 1 0 0 2 1314,7383 465 476
Nidogen-1 precursor (Entactin) - Mus musculus (Mouse) NID1_MOUSE 136603,6 100,00% 12 17 18 0,78% 11,80% AECLNPAQPGR R R 95,00% 2,75 0,217 2,75 0 1 0 0 2 1212,5797 1131 1141
ASLHGGEPTTIIR R Q 95,00% 3 0,431 1,85 0 2 0 0 2 1351,7336 1003 1015
CECVEGYHFSDR R G 95,00% 3,16 0,343 0,0269 0 1 0 0 2 1558,6055 734 745
CGNHAVCNNLPGTFR R C 95,00% 2,27 0,172 -0,146 0 1 0 0 2 1716,77 719 733
GDGQTCYDIDECSEQPSR R C 95,00% 3,65 0,422 0 0 1 0 0 2 2116,8188 701 718
PGYQGDGFR K C 95,00% 2,49 0,343 0 0 1 0 0 2 996,454 828 836
QAEVTFLGHPGK R L 95,00% 2,66 0,463 3,09 0 1 0 0 2 1283,675 517 528
QCVAEGSPQR R V 95,00% 0 0 3,6 0 1 0 0 2 1114,4954 422 431
QTITFQECAHDDAR R P 95,00% 3,32 0,406 0 0 1 0 0 2 1691,745 609 622
TIFWTDSQLDR R I 95,00% 3,59 0,433 0,921 0 2 0 0 2 1381,6753 1032 1042
VLFDTGLVNPR R G 95,00% 2,96 0,274 2,57 0 4 0 0 2 1230,6848 1055 1065
YALSNSIGPVR R D 95,00% 2,41 0,357 2,29 0 2 0 0 2 1176,6377 649 659
100,00% 5 6 6 0,26% 4,98% ASLHGGEPTTIIR R Q 95,00% 3,16 0,273 0 0 2 0 0 2 1351,7336 1003 1015
CGNHAVCNNLPGTFR R C 95,00% 3,47 0,289 0 0 0 1 0 2 1716,77 719 733
PGYQGDGFR K C 95,00% 2,52 0,229 0 0 1 0 0 2 996,454 828 836
QTITFQECAHDDAR R P 95,00% 3,77 0,253 0 0 1 0 0 2 1691,745 609 622
YALSNSIGPVR R D 95,00% 2,84 0,291 0 0 1 0 0 2 1176,6377 649 659
Nidogen-1 precursor (Entactin) - Mus musculus (Mouse) NID1_MOUSE 136603,6 100,00% 14 14 15 0,61% 13,50% AECLNPAQPGR R R 95,00% 2,13 0,037 1,38 0 1 0 0 2 1212,5797 1131 1141
ASLHGGEPTTIIR R Q 95,00% 2,52 0,104 6,37 0 0 1 0 2 1351,7336 1003 1015
CECVEGYHFSDR R G 95,00% 3,2 0,327 0,181 0 1 0 0 2 1558,6055 734 745
CGNHAVCNNLPGTFR R C 95,00% 3,17 0,335 0,181 0 1 0 0 2 1716,77 719 733
EHILGAAGGADAQR R P 95,00% 3,23 0,37 0 0 1 0 0 2 1365,6876 852 865
GNLYWTDWNR R D 95,00% 2,33 0,147 -0,544 0 1 0 0 2 1324,6074 1074 1083
NGFSITGGEFTR K Q 95,00% 2,34 0,313 0,0555 0 1 0 0 2 1285,6178 505 516
NLYYTDWK K T 95,00% 1,68 0,146 1,03 0 1 0 0 2 1102,521 1160 1167
PGPGTQFTCECSIGFR R G 95,00% 2,49 0,319 0 0 1 0 0 2 1813,8004 685 700
QAEVTFLGHPGK R L 95,00% 3,35 0,42 2,43 0 1 0 0 2 1283,675 517 528
TIFWTDSQLDR R I 95,00% 3,13 0,421 1,14 0 1 0 0 2 1381,6753 1032 1042
VIIGLAFDCVDK K V 95,00% 2,63 0,418 0,495 0 1 0 0 2 1349,7142 977 988
VLFDTGLVNPR R G 95,00% 2,62 0,168 3,35 0 1 0 0 2 1230,6848 1055 1065
YALSNSIGPVR R D 95,00% 2,47 0,244 1,51 0 2 0 0 2 1176,6377 649 659
5,22% ASLHGGEPTTIIR R Q 95,00% 3,75 0,305 0 0 0 1 0 2 1351,7336 1003 1015
CGNHAVCNNLPGTFR R C 95,00% 2,53 0,262 0 0 1 0 0 2 1716,77 719 733
EHILGAAGGADAQR R P 95,00% 2,99 0,324 0 0 1 0 0 2 1365,6876 852 865
QAEVTFLGHPGK R L 95,00% 2,94 0,264 0 0 1 0 0 2 1283,675 517 528
YALSNSIGPVR R D 95,00% 2,59 0,251 0 0 1 0 0 2 1176,6377 649 659
Nidogen-1 precursor (Entactin) - Mus musculus (Mouse) NID1_MOUSE 136603,6 100,00% 4 5 5 0,23% 3,94% AECLNPAQPGR R R 95,00% 2,55 0,283 3,26 0 1 0 0 2 1212,5797 1131 1141
CPDNTLGVDCIER R - 95,00% 2,79 0,302 0 0 1 0 0 2 1548,679 1232 1244
EHILGAAGGADAQR R P 95,00% 1,83 0,326 0 0 1 0 0 2 1365,6876 852 865
YALSNSIGPVR R D 95,00% 2,76 0,325 3,05 0 2 0 0 2 1176,6377 649 659
Nidogen-1 precursor (Entactin) - Mus musculus (Mouse) NID1_MOUSE 136603,6 100,00% 7 11 11 0,48% 6,67% AECLNPAQPGR R R 95,00% 2,24 0,217 1,75 0 1 0 0 2 1212,5797 1131 1141
ASLHGGEPTTIIR R Q 95,00% 2,71 0,401 1,39 0 1 2 0 2 1351,7336 1003 1015
CECVEGYHFSDR R G 95,00% 2,79 0,286 -0,806 0 1 0 0 2 1558,6055 734 745
CPDNTLGVDCIER R - 95,00% 2,56 0,278 -0,82 0 1 0 0 2 1548,679 1232 1244
NGFSITGGEFTR K Q 95,00% 2,49 0,313 0,0915 0 1 0 0 2 1285,6178 505 516
VLFDTGLVNPR R G 95,00% 2,8 0,376 2,28 0 1 0 0 2 1230,6848 1055 1065
YALSNSIGPVR R D 95,00% 0 0 3,8 0 3 0 0 2 1176,6377 649 659
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Serotransferrin precursor (Transferrin) (Siderophilin) (Beta-1 metal-binding globulin)TRFE_HORSE 78076,6 100,00% 21 34 35 1,30% 31,30% AACVCQELHNQQASYGK K N 95,00% 4,79 0,471 2,21 0 2 0 0 2 1963,8756 621 637
AVSNFFAGSCVPCADR K T 95,00% 3,47 0,422 0,602 0 1 0 0 2 1757,774 165 180
CGLVPVLAENYETR K S 95,00% 3,32 0,407 0,0269 0 1 0 0 2 1620,8058 423 436
CLADGAGDVAFVK K H 95,00% 3,35 0,248 1,55 0 2 0 0 2 1322,6417 215 227
DCYLASIPSHAVVAR K S 95,00% 3,56 0,433 0,721 0 2 0 0 2 1658,8324 261 275
DDTQCLANLQPTTTYK R T 95,00% 3,29 0,0889 3,29 0 0 1 0 2 1868,8705 660 675
DEYQLLCR R D 95,00% 2,09 0,163 2,55 0 2 0 0 2 1096,51 242 249
DFHLFSSPHGK K D 95,00% 1,65 0,181 2,33 0 2 0 0 2 1271,6173 302 312
EDIRPEVPKDECK R K 95,00% 3,01 0,355 0,509 0 2 0 0 2 1614,78 349 361
FCLFQSATK K D 95,00% 2,53 0,199 3,37 0 2 0 0 2 1101,5404 646 654
GDVAFVK A H 95,00% 1,83 0,124 1,52 1 0 0 0 2 735,4042 221 227
KNSNFQLNQLQGK K K 95,00% 3,91 0,191 0,796 0 1 1 0 2 1518,803 119 131
LLEACTFHRV R - 95,00% 2,51 0,322 2,59 0 1 0 0 2 1245,6415 697 706
NSNFQLNQLQGK K K 95,00% 3,39 0,283 0 0 1 0 0 2 1390,708 120 131
SIVPAPPLVACVKR K T 95,00% 0 0 2,82 0 0 1 0 2 1506,8832 45 58
SKDFHLFSSPHGK K D 95,00% 3,24 0,351 0,131 0 1 0 0 2 1486,7445 300 312
SSSDPDLTWNSLK K G 95,00% 3,02 0,433 4,55 0 1 0 0 2 1449,6863 457 469
TSYLECIK R A 95,00% 2,12 0,176 1,85 1 1 0 0 2 1013,4979 59 66
WCTVSNHEVSK R C 95,00% 2,75 0,173 0,796 0 1 0 0 2 1346,6162 25 35
YLTAVANLR K Q 95,00% 1,32 0,261 1,39 1 4 0 0 2 1020,5842 682 690
YYGYTGAFR R C 95,00% 2,2 0,178 2,14 0 2 0 0 2 1097,5056 541 549
100,00% 10 12 12 0,45% 19,10% AACVCQELHNQQASYGK K N 95,00% 4,2 0,348 0 0 2 0 0 2 1963,8756 621 637
CACSNHEPYFGYSGAFK K C 95,00% 2,62 0,294 0 0 1 0 0 2 1994,8165 198 214
CLADGAGDVAFVK K H 95,00% 3,38 0,297 0 0 1 0 0 2 1322,6417 215 227
DCYLASIPSHAVVAR K S 95,00% 3,1 0,295 0 0 1 0 0 2 1658,8324 261 275
DDTQCLANLQPTTTYK R T 95,00% 4,49 0,348 0 0 0 1 0 2 1868,8705 660 675
HQTVEQNTDGRNPDDWAK K D 95,00% 4,32 0,304 0 0 0 1 0 2 2110,9544 562 579
KNSNFQLNQLQGK K K 95,00% 4,54 0,162 0 0 1 1 0 2 1518,803 119 131
NSNFQLNQLQGK K K 95,00% 3,99 0,285 0 0 1 0 0 2 1390,708 120 131
SKDFHLFSSPHGK K D 95,00% 3,26 0,227 0 0 1 0 0 2 1486,7445 300 312
SSSDPDLTWNSLK K G 95,00% 2,82 0,304 0 0 1 0 0 2 1449,6863 457 469
Aconitate hydratase, mitochondrial precursor (EC 4.2.1.3) (Citrate hydro-lyase) (Aco ACON_RAT 85418,1 100,00% 9 12 12 0,48% 14,90% ADIANLAEEFK R D 95,00% 1,94 0,14 2,01 0 1 0 0 2 1220,6165 313 323
IVYGHLDDPANQEIER K G 95,00% 2,55 0,301 -0,342 0 1 0 0 2 1868,9144 69 84
LEAPDADELPR K S 95,00% 2,33 0,159 0,62 0 1 0 0 2 1225,6067 524 534
LTGTLSGWTSPK K D 95,00% 3,02 0,348 1 0 1 0 0 2 1247,6638 234 245
NAVTQEFGPVPDTAR R Y 95,00% 2,59 0,342 -0,146 0 2 0 0 2 1601,7926 634 648
NINIVR K K 95,00% 1,71 0,0453 1,43 1 0 0 0 2 728,4418 51 56
SQFTITPGSEQIR K A 95,00% 3 0,391 0,62 0 1 0 0 2 1463,7495 412 424
VGLIGSCTNSSYEDMGR R S 95,00% 2,64 0,428 0 0 2 0 0 2 1845,8113 379 395
WVVIGDENYGEGSSR R E 95,00% 3,25 0,366 0,367 0 2 0 0 2 1667,7666 657 671
100,00% 4 4 4 0,16% 7,56% LTGTLSGWTSPK K D 95,00% 3,32 0,259 0 0 1 0 0 2 1247,6638 234 245
SDFDPGQDTYQHPPK R D 95,00% 3,26 0,386 0 0 0 1 0 2 1731,7618 535 549
VGLIGSCTNSSYEDMGR R S 95,00% 2,3 0,363 0 0 1 0 0 2 1845,8113 379 395
WVVIGDENYGEGSSR R E 95,00% 2,39 0,213 0 0 1 0 0 2 1667,7666 657 671
Moesin (Membrane-organizing extension spike protein) - Homo sapiens (Human) MOES_HUMAN 67803,8 100,00% 3 4 4 0,20% 4,85% ALELEQER R K 95,00% 1,53 0,0845 2,54 0 2 0 0 2 987,5112 372 379
AQMVQEDLEK K T 95,00% 2,85 0,123 1,54 0 1 0 0 2 1206,5677 449 458
AQQELEEQTR K R 95,00% 2,86 0,258 1,1 0 1 0 0 2 1231,592 361 370
Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Pyruvate kinase muscle isozyme) - RKPYM_RAT 57800,6 100,00% 6 8 9 0,38% 11,90% AATESFASDPILYR R P 95,00% 2,62 0,393 0 0 1 0 0 2 1540,7648 93 106
APIIAVTR R N 95,00% 1,67 0,279 1,92 1 0 0 0 2 840,5308 448 455
GDYPLEAVR K M 95,00% 2,61 0,339 2,54 0 1 0 0 2 1019,5163 368 376
GIFPVLCK R D 95,00% 1,87 0 2,96 0 1 0 0 2 933,5234 468 475
LDIDSAPITAR R N 95,00% 2,95 0,403 4,85 0 2 0 0 2 1171,6326 33 43
NTGIICTIGPASR R S 95,00% 2,23 0,256 0 0 3 0 0 2 1359,7057 44 56
Pyruvate kinase isozymes M1/M2 (EC 2.7.1.40) (Pyruvate kinase muscle isozyme) - RKPYM_RAT 57800,6 100,00% 5 8 9 0,41% 9,61% APIIAVTR R N 95,00% 1,65 0,178 1,43 1 0 0 0 2 840,5308 448 455
EAEAAVFHR R L 95,00% 2,09 0,106 3,37 0 1 0 0 2 1029,5118 384 392
ITLDNAYMEK K C 95,00% 1,82 0,348 2,01 0 3 0 0 2 1213,5776 142 151
LDIDSAPITAR R N 95,00% 2,97 0,154 1,5 0 1 0 0 2 1171,6326 33 43
NTGIICTIGPASR R S 95,00% 3,73 0,384 2,09 0 3 0 0 2 1359,7057 44 56
T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) - Bos taurus (BoTCPG_BOVIN 60569,2 100,00% 2 2 2 0,09% 4,22% AVAQALEVIPR R T 95,00% 2,94 0,208 2,39 0 1 0 0 2 1166,6898 439 449
TLIQNCGASTIR R L 95,00% 3,53 0,371 -0,447 0 1 0 0 2 1333,6899 450 461
Fascin (Singed-like protein) - Mus musculus (Mouse) FSCN1_MOUSE 54490,2 100,00% 4 4 4 0,19% 9,13% FLVVAHDDGR R W 95,00% 2,13 0,11 1,21 0 1 0 0 2 1128,5802 91 100
LSCFAQSVSPAEK R W 95,00% 3 0,152 1,37 0 1 0 0 2 1423,6892 119 131
YFGGTEDR R L 95,00% 0 0 2,75 0 1 0 0 2 944,4114 111 118
YLAADKDGNVTCER R E 95,00% 2,66 0,326 0 0 1 0 0 2 1611,7439 69 82
Septin-11 - Homo sapiens (Human) SEP11_HUMAN 49381,1 100,00% 3 3 3 0,16% 10,00% AAAQLLQSQAQQSGAQQTK K K 95,00% 3,56 0,451 0 0 1 0 0 2 1957,0105 400 418
FESDPATHNEPGVR K L 95,00% 2,05 0,307 -0,0414 0 1 0 0 2 1555,7142 66 79
SYELQESNVR R L 95,00% 2,5 0,267 2,08 0 1 0 0 2 1224,5859 84 93
Phosphoglycerate kinase 1 (EC 2.7.2.3) - Mus musculus (Mouse) PGK1_MOUSE 44533,1 100,00% 3 3 4 0,19% 8,39% DVLFLK K D 95,00% 1,68 0 1,4 2 0 0 0 2 734,4454 92 97
VLNNMEIGTSLYDEEGAK K I 95,00% 2,58 0,37 0 0 1 0 0 2 1998,9331 247 264
VLPGVDALSNV K - 95,00% 2,76 0,212 1,4 0 1 0 0 2 1083,6051 407 417
Aspartate aminotransferase, cytoplasmic (EC 2.6.1.1) (Transaminase A) (Glutamate AATC_RAT 46411,5 100,00% 4 5 5 0,28% 13,10% ITWSNPPAQGAR R I 95,00% 3,01 0,308 1,17 0 1 0 0 2 1297,6654 294 305
LIADFRDDPDPR K K 95,00% 0 0 3,09 0 0 1 0 2 1429,708 21 32
SCASQLVLGDNSPALR R E 95,00% 2,26 0,254 -1 0 2 0 0 2 1687,8439 82 97
VGGVQSLGGTGALR R I 95,00% 3,4 0,378 4,64 0 1 0 0 2 1271,7074 101 114
100,00% 2 2 3 0,17% 6,30% LIADFRDDPDPR K K 95,00% 3,31 0,245 0 0 0 1 0 2 1429,708 21 32
VGGVQSLGGTGALR R I 95,00% 2,41 0,293 0 0 2 0 0 2 1271,7074 101 114
Creatine kinase M-type (EC 2.7.3.2) (Creatine kinase M chain) (M-CK) - Mus musculu 43027,6 100,00% 1 2 3 0,16% 3,68% GGDDLDPNYVLSSR K V 95,00% 2,88 0,414 -0,505 0 3 0 0 2 1507,7031 117 130
Long-chain specific acyl-CoA dehydrogenase, mitochondrial precursor (EC 1.3.99.13)ACADL_RAT 47855,8 100,00% 5 8 8 0,34% 13,70% AQDTAELFFEDVR K L 95,00% 3,96 0,433 -0,869 0 1 0 0 2 1540,7285 255 267
IFSSEHDIFR R E 95,00% 2,42 0,342 2,36 0 1 0 0 2 1250,6169 52 61
LPASALLGEENK R G 95,00% 3,73 0,323 3,54 0 4 0 0 2 1241,6743 268 279
SGSDWILNGSK R V 95,00% 0 0 2,55 0 1 0 0 2 1163,5698 191 201
VQPIYGGTNEIMK R E 95,00% 2,51 0,432 0 0 1 0 0 2 1465,7363 407 419
100,00% 2 5 6 0,26% 5,12% IFSSEHDIFR R E 95,00% 2,53 0,251 0 0 1 0 0 2 1250,6169 52 61
LPASALLGEENK R G 95,00% 3,5 0,339 0 0 5 0 0 2 1241,6743 268 279
Serum albumin precursor (Allergen Equ c 3) - Equus caballus (Horse) ALBU_HORSE 68581,9 100,00% 6 6 7 0,35% 9,56% APQVSTPTLVEIGR K T 95,00% 2,27 0,409 -1,42 0 2 0 0 2 1467,8174 438 451
CCTDSLAER K R 95,00% 2,16 0,308 3,15 0 1 0 0 2 1111,4514 499 507
LPCSENHLALALNR R L 95,00% 2,69 0,315 0 0 1 0 0 2 1607,8329 469 482
QIKKQSALAELVK K H 95,00% 0 0 4,13 0 0 1 0 2 1438,8636 545 557
QSALAELVK K H 95,00% 1,91 0,166 2,26 0 1 0 0 2 958,5574 549 557
TYEATLEK K C 95,00% 1,59 0,282 1,75 1 0 0 0 2 954,4784 375 382
Macrophage-capping protein (Actin-regulatory protein CAP-G) - Rattus norvegicus (RCAPG_RAT 38781,7 99,10% 2 3 3 0,16% 6,59% TTSGTTPAAIR K K 95,00% 1,95 0,0501 1,13 0 1 0 0 2 1075,5749 128 138
VSDATGQMNLTK K V 95,00% 3,11 0,241 1,1 0 2 0 0 2 1280,6157 255 266
Aldose reductase (EC 1.1.1.21) (AR) (Aldehyde reductase) - Rattus norvegicus (Rat) ALDR_RAT 35779,7 100,00% 3 3 3 0,16% 7,91% EVGVALQEK K L 95,00% 1,91 0,163 3,38 0 1 0 0 2 972,5367 54 62
TTAQVLIR K F 95,00% 2,8 0,235 4,05 0 1 0 0 2 901,5472 244 251
VAIDMGYR K H 95,00% 2,02 0,194 3,48 0 1 0 0 2 940,4563 34 41
100,00% 2 2 2 0,10% 5,38% EVGVALQEK K L 95,00% 2,17 0,249 0 0 1 0 0 2 972,5367 54 62
TTAQVLIR K F 95,00% 3,04 0,12 0 0 1 0 0 2 901,5472 244 251
Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) - Columba livia G3P_COLLI 35748,9 100,00% 2 2 2 0,10% 8,11% GAAQNIIPASTGAAK R A 95,00% 3,09 0,154 0,569 0 1 0 0 2 1369,7441 199 213
VVDLMVHMASKE R - 95,00% 2,56 0,232 0 0 1 0 0 2 1390,671 322 333
Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-phosphate isomerase) - Rattu TPIS_RAT 26830,7 100,00% 3 4 4 0,25% 16,50% CNVSEGVAQCTR K I 95,00% 1,94 0,264 0 0 1 0 0 2 1380,6001 195 206
HIFGESDELIGQK R V 95,00% 2,51 0,296 -0,748 0 1 1 0 2 1472,7388 101 113
VTNGAFTGEISPGMIK K D 95,00% 2,23 0,263 0 0 1 0 0 2 1637,8212 70 85
KCRM_MOUSE,KCRM_RAT
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ATP synthase D chain, mitochondrial (EC 3.6.3.14) - Rattus norvegicus (Rat) ATP5H_RAT 18746 100,00% 3 4 5 0,25% 24,20% ANVDKPGLVDDFK R N 95,00% 2,78 0,329 -0,74 0 1 1 0 2 1417,7329 59 71
NCAQFVTGSQAR K V 95,00% 3,05 0,262 -0,875 0 2 0 0 2 1338,6224 100 111
YTALVDAEEKEDVK K N 95,00% 3,18 0,292 0 0 1 0 0 2 1609,7963 86 99
99,80% 2 2 2 0,10% 16,80% ANVDKPGLVDDFK R N 95,00% 2,98 0,338 0 0 1 0 0 2 1417,7329 59 71
YTALVDAEEKEDVK K N 95,00% 3,52 0,323 0 0 1 0 0 2 1609,7963 86 99
Myosin regulatory light chain 2, ventricular/cardiac muscle isoform (MLC-2) (MLC-2v)MLRV_BOVIN 18963,3 100,00% 5 6 6 0,32% 24,10% DTFAALGR R V 95,00% 1,72 0,0754 1,19 1 0 0 0 2 850,4424 51 58
EAFTIMDQNR K D 95,00% 2,78 0,133 0,215 0 1 0 0 2 1240,5632 31 40
EMLTTQAER K F 95,00% 2 0,101 1,16 0 1 0 0 2 1094,5153 121 129
NLVHIITHGEEK K - 95,00% 2,73 0,215 -0,204 0 2 0 0 2 1389,7493 154 165
NLVHIITHGEEKD K - 95,00% 2,87 0,384 0 0 1 0 0 2 1504,7762 154 166
T-complex protein 1 subunit zeta (TCP-1-zeta) (CCT-zeta) (CCT-zeta-1) (Tcp20) (HT TCPZ_HUMAN,TCPZ_PONPY 58007,3 100,00% 3 4 4 0,19% 5,46% ALQFLEEVK K V 95,00% 1,91 0 1,89 0 1 0 0 2 1076,5994 130 138
MLVSGAGDIK K L 95,00% 2,65 0,207 3,02 0 1 0 0 2 1006,5244 46 55
TEVNSGFFYK K S 95,00% 1,82 0,0381 2,11 0 2 0 0 2 1191,5686 242 251
Myosin regulatory light chain 2A, cardiac muscle isoform (G2) (MLC-2A) - Gallus galluMLRA_CHICK 18688,1 99,80% 2 5 18 3,49% 9,09% GADPEETILNAFK K V 95,00% 3,84 0,21 7,2 0 8 0 0 2 1404,7013 92 104
LKGADPEETILNAFK K V 95,00% 4 0,331 8,52 0 4 6 0 2 1645,8804 90 104
Tropomyosin alpha-4 chain (Tropomyosin-4) (TM-4) - Rattus norvegicus (Rat) TPM4_RAT 28492,4 100,00% 4 7 8 1,39% 17,70% IQLVEEELDRAQER R L 95,00% 1,88 0,0703 6,51 0 0 1 0 2 1727,8929 56 69
LVILEGELER K A 95,00% 2,68 0,292 4,92 0 1 0 0 2 1170,6736 133 142
LVILEGELERAEER K A 95,00% 3,77 0,313 5,3 0 1 3 0 2 1655,897 133 146
SSDLEEELKNVTNNLK K S 95,00% 4,75 0,281 6,6 0 2 0 0 2 1832,9242 154 169
Actin-1 - Aedes aegypti (Yellowfever mosquito) ACT1_AEDAE 41773,6 100,00% 5 9 24 1,89% 26,60% DLTDYLMK R I 95,00% 2,64 0,131 2,54 3 3 0 0 2 998,4871 185 192
DLYANTVLSGGTTMYPGIADR K M 95,00% 5,28 0,312 7 0 1 1 0 2 2231,0659 293 313
IWHHTFYNELR K V 95,00% 2,22 0,0191 3 0 0 3 0 2 1515,7496 86 96
KDLYANTVLSGGTTMYPGIADR R M 95,00% 4,96 0,219 10,2 0 0 1 0 2 2359,1609 292 313
LDLAGRDLTDYLMK R I 95,00% 2,31 0 7,46 0 0 2 0 2 1639,8369 179 192
SYELPDGQVITIGNER K F 95,00% 3,83 0,318 6,08 0 15 4 0 2 1790,8926 240 255
VAPEEHPVLLTEAPLNPK R A 95,00% 4,52 0,285 1,68 0 6 13 0 2 1954,0653 97 114
VAPEEHPVLLTEAPLNPKANR R E 95,00% 3,49 0,086 2,96 0 0 1 0 2 2295,2463 97 117
YPNEHGIITNWDDMEK K I 95,00% 2,42 -0,0819 3,52 0 1 0 0 2 1961,8706 70 85
Actin, muscle 2/4/4A - Halocynthia roretzi (Sea squirt) ACT2_HALRO 41997 100,00% 9 17 45 3,54% 28,30% DLTDYLMK R I 95,00% 2,64 0,131 2,54 3 3 0 0 2 998,4871 187 194
DLYANNVLSGGTTMYPGIADR K M 95,00% 4,87 0,248 5,68 0 1 1 0 2 2244,061 295 315
GYSFVTTAER R E 95,00% 3,05 0,317 4,68 0 2 0 0 2 1130,5482 200 209
IWHHTFYNELR K V 95,00% 2,22 0,0191 3 0 0 3 0 2 1515,7496 88 98
KDLYANNVLSGGTTMYPGIADR R M 95,00% 5,2 0,158 2,85 0 0 2 0 2 2372,156 294 315
LDLAGRDLTDYLMK R I 95,00% 2,31 0 7,46 0 0 2 0 2 1639,8369 181 194
SYELPDGQVITIGNER K F 95,00% 3,83 0,318 6,08 0 15 4 0 2 1790,8926 242 257
VAPEEHPTLLTEAPLNPK R A 95,00% 3,84 0,18 5,3 0 4 4 0 2 1956,0447 99 116
YPIEHGIITNWDDMEK K I 95,00% 3,87 0,116 2,75 0 0 1 0 2 1976,9066 72 87
Tropomyosin-1 alpha chain (Alpha-tropomyosin) - Homo sapiens (Human) TPM1_HUMAN 32692 100,00% 9 16 42 5,10% 33,80% CAELEEELK K T 95,00% 0 0 3,52 1 5 0 0 2 1103,4933 190 198
CAELEEELKTVTNNLK K S 95,00% 3,43 0,334 6,11 0 0 3 0 2 1890,9484 190 205
GTEDELDKYSEALKDAQEK K L 95,00% 4,3 0,137 7,42 0 0 3 0 2 2169,02 52 70
IQLVEEELDR R A 95,00% 2,79 0,155 4,16 0 5 0 0 2 1243,6536 92 101
IQLVEEELDRAQER R L 95,00% 2,15 0,0281 4,15 0 0 1 0 2 1727,8929 92 105
LVIIESDLERAEER K A 95,00% 1,88 0,0172 3,59 0 0 1 0 2 1671,8918 169 182
MEIQEIQLK K E 95,00% 2,72 0,0549 5 0 1 0 0 2 1131,6086 141 149
QLEDELVSLQK K K 95,00% 0 0 4,11 1 11 0 0 2 1284,669 38 48
SIDDLEDELYAQK K L 95,00% 4,67 0,428 8,26 0 6 4 0 2 1538,7228 252 264
Vimentin - Bos taurus (Bovine) VIME_BOVIN 53710,8 100,00% 2 2 4 0,42% 4,72% ILLAELEQLK K G 95,00% 3,34 0,222 5,52 0 3 0 0 2 1169,7148 130 139
VESLQEEIAFLK K K 95,00% 3,19 0,192 6,85 0 1 0 0 2 1405,7581 224 235
Vimentin - Bos taurus (Bovine) VIME_BOVIN 53710,8 100,00% 2 2 2 0,21% 4,51% ILLAELEQLK K G 95,00% 3,51 0,209 6,19 0 1 0 0 2 1169,7148 130 139
MALDIEIATYR K K 95,00% 3,44 0,276 6,16 0 1 0 0 2 1311,662 391 401
ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) - Homo sapiens (HATPB_HUMAN 56542,5 100,00% 8 14 27 4,86% 22,90% AIAELGIYPAVDPLDSTSR R I 95,00% 3,15 0,0584 2,47 0 1 0 0 2 1988,0343 388 406
EGNDLYHEMIESGVINLK R D 95,00% 3,42 0 6,3 0 0 2 0 2 2076,9912 242 259
FTQAGSEVSALLGR R I 95,00% 3,67 0,279 8,22 0 4 2 0 2 1435,7545 311 324
LVLEVAQHLGESTVR R T 95,00% 4,79 0,53 9,75 0 4 5 0 2 1650,918 95 109
TVLIMELINNVAK K A 95,00% 4,19 0,335 8,96 0 3 0 0 2 1473,8351 213 225
VALTGLTVAEYFR R D 95,00% 3,97 0,077 8,13 0 1 0 0 2 1439,7899 282 294
VLDSGAPIKIPVGPETLGR K I 95,00% 4,67 0,375 16 0 0 2 0 2 1919,097 125 143
VVDLLAPYAK K G 95,00% 2,62 0,0835 4,37 0 3 0 0 2 1088,6357 189 198
ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) - Homo sapiens (HATPB_HUMAN 56542,5 100,00% 10 16 37 12,90% 29,10% AIAELGIYPAVDPLDSTSR R I 95,00% 3,15 0,0598 8,28 0 1 0 0 2 1988,0343 388 406
EGNDLYHEMIESGVINLK R D 95,00% 0 0 5,19 0 0 1 0 2 2076,9912 242 259
FTQAGSEVSALLGR R I 95,00% 4,36 0,24 9,7 0 4 2 0 2 1435,7545 311 324
IMNVIGEPIDER R G 95,00% 3,07 0,0891 5,54 0 2 0 0 2 1385,7101 144 155
IPSAVGYQPTLATDMGTMQER R I 95,00% 6,72 0,368 11,7 0 0 1 0 2 2298,0749 325 345
LVLEVAQHLGESTVR R T 95,00% 4,63 0,466 10,5 0 5 7 0 2 1650,918 95 109
TVLIMELINNVAK K A 95,00% 4,7 0,281 8,96 0 3 0 0 2 1457,8402 213 225
VALTGLTVAEYFR R D 95,00% 3,86 0,0124 6,54 0 0 1 0 2 1439,7899 282 294
VLDSGAPIKIPVGPETLGR K I 95,00% 2,35 0,0937 5 0 1 3 0 2 1919,097 125 143
VVDLLAPYAK K G 95,00% 2,26 0,171 2,64 0 6 0 0 2 1088,6357 189 198
Vimentin (Fragment) - Cricetulus griseus (Chinese hamster) VIME_CRIGR 51831,8 100,00% 13 19 51 7,66% 22,50% EEAESTLQSFR R Q 95,00% 1,95 0 2,92 0 1 0 0 2 1296,6072 179 189
ETNLESLPLVDTHSK R R 95,00% 0 0 6,92 0 1 0 0 2 1664,8496 407 421
ETNLESLPLVDTHSKR R T 95,00% 0 0 3,62 0 0 1 0 2 1838,9613 407 422
ILLAELEQLK K G 95,00% 2,92 0,173 4,92 0 15 0 0 2 1169,7148 112 121
ILLAELEQLKGQGK K S 95,00% 4,73 0,327 6,62 0 4 3 0 2 1539,9114 112 125
ISLPLPNFSSLNLR R E 95,00% 2,82 0,253 3,34 0 1 0 0 2 1570,8957 393 406
KVESLQEEIAFLK R K 95,00% 5,16 0,304 9,1 0 3 4 0 2 1533,8529 205 217
KVESLQEEIAFLKK R L 95,00% 5,09 0,204 8,38 0 0 6 0 2 1661,9479 205 218
MALDIEIATYR K K 95,00% 3,95 0,383 6,92 0 3 0 0 2 1311,662 373 383
QVQSLTCEVDALK R G 95,00% 0 0 4,66 0 4 0 0 2 1473,7262 304 316
QVQSLTCEVDALKGTNESLER R Q 95,00% 2,94 0,311 2,85 0 0 2 0 2 2377,167 304 324
VESLQEEIAFLK K K 95,00% 4,3 0,35 7,55 0 2 0 0 2 1405,7581 206 217
VESLQEEIAFLKK K L 95,00% 2,32 0,229 0,42 0 0 1 0 2 1533,853 206 218
Calreticulin precursor (CRP55) (Calregulin) (HACBP) (ERp60) (CALBP) (Calcium-bindi CALR_RAT 47979 100,00% 8 14 19 1,76% 17,80% DEDEDEEDEKEEDEEDATGQAK R D 95,00% 4,61 0,418 2,8 0 0 1 0 2 2554,9556 392 413
DPDAAKPEDWDER K A 95,00% 0 0 3,82 0 0 2 0 2 1543,6667 210 222
EQFLDGDAWTNR K W 95,00% 2,83 0,468 8,19 0 3 0 0 2 1451,6556 25 36
FVLSSGK K F 95,00% 1,89 0,201 1,96 1 0 0 0 2 737,4197 49 55
IKDPDAAKPEDWDER K A 95,00% 3,64 0,375 4,17 0 2 5 0 2 1784,846 208 222
KVHVIFNYK K G 95,00% 2,21 0,343 2,29 0 1 0 0 2 1147,6628 143 151
LFPGGLDQK K D 95,00% 2,37 0,257 3,7 0 3 0 0 2 974,5313 112 120
VHVIFNYK K G 95,00% 1,83 0,286 2,26 0 1 0 0 2 1019,5678 144 151
Alpha-1-antiproteinase 2 precursor (Alpha-1-antitrypsin 2) (Alpha-1-proteinase inhib A1AT2_HORSE 46925,8 100,00% 6 8 11 0,72% 14,00% AVLTIDEK K G 95,00% 2,19 0,165 1,96 2 0 0 0 2 888,5043 363 370
DTVLALVNYIFFK K G 95,00% 3,18 0,283 1,48 0 1 0 0 2 1542,8572 206 218
IAPNLADFAFSLYR K H 95,00% 4,61 0,502 4,28 0 4 0 0 2 1597,838 53 66
LLDKFLEDVK K K 95,00% 0 0 4,36 0 1 0 0 2 1219,6941 153 162
SPLFVGK K V 95,00% 1,54 0,028 1,28 2 0 0 0 2 747,4406 408 414
SPLFVGKVVDPTQK K - 95,00% 2,5 0,316 0,432 0 0 1 0 2 1514,8586 408 421
Alpha-1-antiproteinase 2 precursor (Alpha-1-antitrypsin 2) (Alpha-1-proteinase inhib A1AT2_HORSE 46925,8 100,00% 5 6 6 0,58% 13,30% HSSFVNVHLPK R L 95,00% 0 0 5,01 0 2 0 0 2 1264,6803 307 317
IAPNLADFAFSLYR K H 95,00% 2,26 0,351 1,07 0 1 0 0 2 1597,838 53 66
LQHLEDTLTK K G 95,00% 2,89 0,284 4,55 0 1 0 0 2 1197,6482 287 296
QADLSGITEEVPLTVSK R A 95,00% 2,64 0,336 4,27 0 1 0 0 2 1786,9441 342 358
QADLSGITEEVPLTVSKALHK R A 95,00% 0 0 4 0 0 1 0 2 2236,219 342 362
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Protein disulfide-isomerase A3 precursor (EC 5.3.4.1) (Disulfide isomerase ER-60) (EPDIA3_RAT 56607,5 100,00% 12 26 32 2,72% 30,30% DGEEAGAYDGPR R T 95,00% 2,37 0,327 2,8 0 5 0 0 2 1236,5135 108 119
EATNPPIIQEEKPK R K 95,00% 2,85 0,5 6,1 0 5 0 0 2 1593,8492 483 496
ELNDFISYLQR R E 95,00% 2,06 0,267 1,19 0 3 0 0 2 1397,7065 472 482
FLQEYFDGNLK R R 95,00% 3,31 0,267 6,82 0 1 0 0 2 1373,6742 352 362
FLQEYFDGNLKR R Y 95,00% 3,34 0,287 4,75 0 1 0 0 2 1529,7753 352 363
KFISDKDASVVGFFR K D 95,00% 0 0 4,48 0 0 1 0 2 1715,912 147 161
LAPEYEAAATR R L 95,00% 2,63 0,275 5,32 0 4 0 0 2 1191,6011 63 73
MDATANDVPSPYEVK K G 95,00% 4,28 0,405 8,15 0 3 0 0 2 1652,7478 434 448
SEPIPETNEGPVK K V 95,00% 1,74 0,0762 3,14 0 1 0 0 2 1396,6963 367 379
TADGIVSHLK R K 95,00% 2,81 0,352 4,72 0 1 0 0 2 1040,5742 120 129
TFSHELSDFGLESTTGEIPVVAIR K T 95,00% 2,11 0,0827 7,35 0 0 2 0 2 2605,3149 306 329
VVVAESFDDIVNAEDK K D 95,00% 5,24 0,497 9,8 0 4 1 0 2 1749,8546 380 395
Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural enolaENOA_RAT 47111 100,00% 15 54 88 2,68% 44,50% AAVPSGASTGIYEALELR R D 95,00% 4,72 0,501 4,57 0 8 1 0 2 1804,9447 33 50
AGKYDLDFKSPDDASR R Y 95,00% 4,77 0,309 8 0 2 1 0 2 1784,8458 254 269
DATNVGDEGGFAPNILENK K E 95,00% 4,06 0,136 8,51 0 4 0 0 2 1960,9254 203 221
DATNVGDEGGFAPNILENKEALELLK K S 95,00% 4,21 0,428 3,25 0 0 1 0 2 2757,3945 203 228
GNPTVEVDLYTAK R G 95,00% 2,4 0,0539 3,96 0 7 0 0 2 1406,7169 16 28
HIADLAGNPEVILPVPAFNVINGGSHAGNK R L 95,00% 7,22 0,024 5,51 0 0 4 0 2 3021,5911 133 162
IDQLMIEMDGTENK K S 95,00% 3,82 0 2,17 0 7 0 0 2 1652,7515 90 103
IGAEVYHNLK R N 95,00% 2,96 0,19 1,39 0 3 0 0 2 1143,6163 184 193
LAMQEFMILPVGASSFR K E 95,00% 3,44 0,0674 3,1 0 10 2 0 2 1896,9717 163 179
LAQSNGWGVMVSHR K S 95,00% 2,6 0 5,41 0 4 1 0 2 1541,7645 359 372
LNVVEQEK K I 95,00% 2,23 0,0166 4,18 0 8 0 0 2 958,5209 82 89
LNVVEQEKIDQLMIEMDGTENK K S 95,00% 6,11 0,418 3,85 0 0 1 0 2 2608,249 82 103
VNQIGSVTESLQACK K L 95,00% 3,92 0,288 4,2 0 9 1 0 2 1633,822 344 358
YDLDFKSPDDASR K Y 95,00% 3,95 0,179 3,7 0 3 0 0 2 1528,6923 257 269
YITPDQLADLYK R S 95,00% 2,42 0,12 5,24 0 11 0 0 2 1439,7425 270 281
Laminin subunit alpha-1 precursor (Laminin A chain) - Mus musculus (Mouse) LAMA1_MOUSE 338149,2 100,00% 9 10 11 0,65% 3,79% ADNEVICTSYYSK R L 95,00% 3,14 0,337 1,36 0 1 0 0 2 1549,6844 183 195
AEGLSLQPYEEYFNVVR R L 95,00% 3,78 0,426 3,59 0 1 0 0 2 2013,9919 630 646
ALLHAPTGSYSDGQEHSISLVR K N 95,00% 3,16 0,242 2,59 0 0 2 0 2 2338,1792 2576 2597
DLIYVGGLPHSK K A 95,00% 2,43 0,342 0,658 0 1 0 0 2 1298,7111 2440 2451
ITATYQPR R A 95,00% 1,71 0,103 2,42 0 2 0 0 2 949,5108 2969 2976
LYLGGLPSHYR K A 95,00% 2,03 0,168 1,77 0 1 0 0 2 1275,6851 2845 2855
NGVLLGISSAK K V 95,00% 1,9 0,202 1,82 0 1 0 0 2 1058,6211 2935 2945
TLNADLMTLSHR R D 95,00% 0 0 2,96 0 1 0 0 2 1387,7006 240 251
VSHPALLSDGK K W 95,00% 2,07 0,294 0,854 0 1 0 0 2 1123,6113 2795 2805
Elongation factor 2 (EF-2) - Cricetulus griseus (Chinese hamster) EF2_CRIGR 95380 100,00% 4 8 10 0,59% 5,48% CLYASVLTAQPR R L 95,00% 3,1 0,424 4,62 0 5 0 0 2 1378,7154 728 739
ETVSEESNVLCLSK R S 95,00% 3,99 0,463 5,66 0 2 0 0 2 1594,7634 581 594
IMGPNYTPGK R K 95,00% 2,35 0,25 1,35 0 1 0 0 2 1093,5354 429 438
VFSGVVSTGLK R V 95,00% 3,39 0,36 7,27 0 2 0 0 2 1093,6257 416 426
Serotransferrin precursor (Transferrin) (Siderophilin) (Beta-1 metal-binding globulin)TRFE_HORSE 78076,6 100,00% 37 93 166 3,92% 54,80% AACVCQELHNQQASYGK K N 95,00% 5,9 0,582 8,04 0 1 1 0 2 1963,8756 621 637
APNHAVVSR R K 95,00% 1,85 0,401 2,4 0 2 0 0 2 950,5171 609 617
AVSNFFAGSCVPCADR K T 95,00% 4,51 0,497 5,52 0 16 0 0 2 1757,774 165 180
CACSNHEPYFGYSGAFK K C 95,00% 4,36 0,537 5,28 0 3 1 0 2 1994,8165 198 214
CGLVPVLAENYETR K S 95,00% 0 0 5,27 0 9 0 0 2 1603,7793 423 436
CLADGAGDVAFVK K H 95,00% 0 0 3,41 0 16 0 0 2 1305,6152 215 227
CLVEKGDVAFVK R H 95,00% 3,03 0 3,3 0 5 0 0 2 1364,725 550 561
DCYLASIPSHAVVAR K S 95,00% 3,69 0,396 3,42 0 2 0 0 2 1658,8324 261 275
DDTQCLANLQPTTTYK R T 95,00% 5,28 0,492 5,03 0 6 0 0 2 1868,8705 660 675
DEYQLLCR R D 95,00% 2,39 0,177 0,77 0 1 0 0 2 1096,51 242 249
DFHLFSSPHGK K D 95,00% 2,97 0,386 1,17 0 1 0 0 2 1271,6173 302 312
DLKSENFK K L 95,00% 1,98 0,145 2,5 0 2 0 0 2 980,5054 580 587
DLLFKDSALGFLR K I 95,00% 3,19 0,0742 3,41 0 2 0 0 2 1494,8323 313 325
DLLFRDDTQCLANLQPTTTYK K T 95,00% 2,79 0,332 2,68 0 0 1 0 2 2513,2349 655 675
EDIRPEVPKDECK R K 95,00% 1,88 0,277 0,041 0 3 0 0 2 1614,78 349 361
FCLFQSATK K D 95,00% 2,48 0,235 3,68 0 3 0 0 2 1101,5404 646 654
GDVAFVK K H 95,00% 1,83 0,0792 2,02 1 0 0 0 2 735,4042 555 561
HQTVEQNTDGRNPDDWAK K D 95,00% 3,13 0,398 3,46 0 3 2 0 2 2110,9544 562 579
KNSNFQLNQLQGK K K 95,00% 2,47 0,124 2,06 0 1 0 0 2 1518,803 119 131
KSVDEYKDCYLASIPSHAVVAR R S 95,00% 5,18 0,421 0,886 0 0 2 0 2 2508,2556 254 275
LLCPDGTR K K 95,00% 1,8 0,149 2,57 0 3 0 0 2 931,4673 588 595
LLEACTFHR R - 95,00% 2,47 0,2 0,377 0 2 0 0 2 1146,5731 697 705
LLEACTFHRV R - 95,00% 1,81 0,192 1,7 0 3 0 0 2 1245,6415 697 706
NGSHCPDKFCLFQSATK K D 95,00% 3,26 0,43 2,5 0 0 1 0 2 1996,9011 638 654
NSNFQLNQLQGK K K 95,00% 3,73 0,321 1,39 0 9 0 0 2 1390,708 120 131
RTSYLECIK K A 95,00% 2,3 0,117 2,89 0 4 0 0 2 1169,599 58 66
SAGWNIPIGLLYWQLPEPR R E 95,00% 4,97 0,475 6,82 0 3 1 0 2 2210,1765 141 159
SIVPAPPLVACVK K R 95,00% 2,46 0,356 4,24 0 5 0 0 2 1350,7821 45 57
SKDFHLFSSPHGK K D 95,00% 3,85 0,433 4,55 0 3 0 0 2 1486,7445 300 312
SSSDPDLTWNSLK K G 95,00% 3,56 0,38 3,82 0 8 0 0 2 1449,6863 457 469
SVDEYKDCYLASIPSHAVVAR K S 95,00% 6,29 0,503 4,89 0 0 6 0 2 2380,1606 255 275
SVDGKEDLIWGLLNQAQEHFGTEK R S 95,00% 3,97 0,329 3,16 0 0 1 0 2 2714,3428 276 299
TAGWNIPMGLLYSEIK R H 95,00% 2,74 0,118 3,03 0 2 0 0 2 1792,931 481 496
TAVPNLCQLCVGK R G 95,00% 2,7 0,469 5,21 0 9 0 0 2 1459,7404 181 193
TSYLECIK R A 95,00% 1,86 0,216 -0,255 2 2 0 0 2 1013,4979 59 66
YLTAVANLR K Q 95,00% 1,7 0,228 1,08 0 11 0 0 2 1020,5842 682 690
YYGYTGAFR R C 95,00% 1,74 0,316 -0,74 1 6 0 0 2 1097,5056 541 549
Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Cytosolic malate dehydrogenase) MDHC_MOUSE 36494,1 100,00% 5 10 14 1,96% 21,60% DLDVAVLVGSMPR K R 95,00% 3,04 0,395 5,5 0 1 0 0 2 1387,7257 80 92
FVEGLPINDFSR K E 95,00% 2,24 0,379 5,66 0 5 0 0 2 1393,7117 299 310
GEFITTVQQR K G 95,00% 3,29 0,327 4,7 0 4 0 0 2 1178,6172 221 230
NVIIWGNHSSTQYPDVNHAK K V 95,00% 0 0 6,42 0 0 2 0 2 2280,1162 180 199
VIVVGNPANTNCLTASK K S 95,00% 4,51 0,528 12 0 2 0 0 2 1757,922 126 142
78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa protein 5) GRP78_HUMAN 72316,7 100,00% 6 10 13 2,39% 12,70% DAGTIAGLNVMR K I 95,00% 3,19 0,332 5,96 0 2 0 0 2 1233,6263 186 197
ITPSYVAFTPEGER R L 95,00% 3,63 0,526 2,05 0 5 0 0 2 1566,7806 61 74
KKELEEIVQPIISK K L 95,00% 3,29 0,119 5,19 0 0 2 0 2 1653,9795 620 633
TFAPEEISAMVLTK K M 95,00% 2,95 0,0552 8 0 1 0 0 2 1552,7933 139 152
TWNDPSVQQDIK R F 95,00% 3,54 0,322 5,7 0 1 0 0 2 1430,6918 102 113
VTHAVVTVPAYFNDAQR K Q 95,00% 0 0 10,5 0 0 2 0 2 1887,9716 165 181
Tropomyosin beta chain (Tropomyosin 2) (Beta-tropomyosin) - Homo sapiens (HumaTPM2_HUMAN 32833,7 100,00% 9 14 20 2,48% 23,20% CKQLEEEQQALQK R K 95,00% 3,59 0,442 4,4 0 1 0 0 2 1631,8066 36 48
CKQLEEEQQALQKK R L 95,00% 0 0 4,27 0 0 1 0 2 1759,9016 36 49
IQLVEEELDR R A 95,00% 2,76 0,276 6,05 0 2 0 0 2 1243,6536 92 101
KATDAEADVASLNR K R 95,00% 4,25 0,357 7,62 0 2 0 0 2 1460,7346 77 90
LEEAEKAADESER K G 95,00% 0 0 4,52 0 0 1 0 2 1476,6819 113 125
LVILEGELER K S 95,00% 2,87 0,21 4,4 0 4 0 0 2 1170,6736 169 178
QLEEEQQALQK K K 95,00% 0 0 5,4 0 4 0 0 2 1326,6544 38 48
RIQLVEEELDR R A 95,00% 2,96 0,206 4,25 0 2 0 0 2 1399,7546 91 101
RIQLVEEELDRAQER R L 95,00% 3,78 0,404 1,39 0 0 3 0 2 1883,994 91 105
Desmin - Mesocricetus auratus (Golden hamster) DESM_MESAU 53421,5 100,00% 20 43 53 8,56% 43,50% ADVDAATLAR R I 95,00% 3,98 0,403 6,89 0 5 0 0 2 1002,522 212 221
DGEVVSEATQQQHEVL R - 95,00% 3,58 0,453 4,6 0 4 0 0 2 1768,8356 454 469
DNLIDDLQR R L 95,00% 2,41 0,283 4,09 0 2 0 0 2 1101,5543 180 188
EEAENNLAAFR R A 95,00% 2,59 0,216 6,01 0 3 0 0 2 1263,5969 201 211
EYQDLLNVK R M 95,00% 1,63 0,193 1,89 0 1 0 0 2 1121,5845 386 394
FASEASGYQDNIAR R L 95,00% 4,66 0,529 8,08 0 3 0 0 2 1528,7031 355 368
FASEASGYQDNIARLEEEIR R H 95,00% 2,6 0,278 5,03 0 0 1 0 2 2298,1001 355 374
FLEQQNAALAAEVNR R L 95,00% 5,36 0,459 9,68 0 2 0 0 2 1673,861 127 141
HQIQSYTCEIDALK R G 95,00% 4,09 0,45 6,14 0 1 5 0 2 1705,8223 325 338
INLPIQTFSALNFR R E 95,00% 3,82 0,464 8,38 0 3 0 0 2 1633,9065 415 428
LQEEIQLR K E 95,00% 2,44 0,148 3,5 0 3 0 0 2 1028,5742 193 200
MALDVEIATYR K K 95,00% 3,43 0,472 6,14 0 4 0 0 2 1297,6464 395 405
NISEAEEWYK K S 95,00% 3,27 0,334 4,13 0 3 0 0 2 1268,58 287 296
QVEVLTNQR R A 95,00% 1,91 0,193 3,5 0 3 0 0 2 1086,5908 164 172
TNEKVELQELNDR R F 95,00% 2,68 0,279 3,28 0 3 0 0 2 1587,798 105 117
VAELYEEEMR R E 95,00% 3,22 0,452 4,72 0 2 0 0 2 1268,5834 150 159
VAELYEEEMRELR R R 95,00% 1,98 0,269 -0,0414 0 0 1 0 2 1682,806 150 162
VAELYEEEMRELRR R Q 95,00% 2,21 0,108 3,85 0 0 1 0 2 1838,9071 150 163
VDVERDNLIDDLQR R L 95,00% 2,47 0,282 0,854 0 0 1 0 2 1699,8617 175 188
VSDLTQAANKNNDALR K Q 95,00% 1,8 0 6,43 0 0 2 0 2 1729,8833 299 314
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Vimentin (Fragment) - Cricetulus griseus (Chinese hamster) VIME_CRIGR 51831,8 100,00% 27 64 87 4,56% 53,40% DGQVINETSQHHDDLE R - 95,00% 3,2 0,266 3,7 0 3 0 0 2 1836,8002 433 448
EEAESTLQSFR R Q 95,00% 2,44 0,453 5,41 0 4 0 0 2 1296,6072 179 189
ETNLESLPLVDTHSK R R 95,00% 2,14 0,211 2,77 0 2 0 0 2 1682,8602 407 421
EYQDLLNVK R M 95,00% 1,93 0,292 1,44 0 3 0 0 2 1121,5845 364 372
FADLSEAANR K N 95,00% 2,2 0,312 2,52 0 5 0 0 2 1093,5278 277 286
FADYIDK R V 95,00% 2,11 0,11 1,48 2 0 0 0 2 871,4202 96 102
FADYIDKVR R F 95,00% 3,14 0,24 4,18 0 2 0 0 2 1126,5898 96 104
ILLAELEQLK K G 95,00% 2,65 0,229 4,28 0 5 0 0 2 1169,7148 112 121
ILLAELEQLKGQGK K S 95,00% 3,79 0,405 6,6 0 3 0 0 2 1539,9114 112 125
ISLPLPNFSSLNLR R E 95,00% 2,03 0,295 1,89 0 5 0 0 2 1570,8957 393 406
KVESLQEEIAFLK R K 95,00% 4,15 0,288 0,244 0 2 4 0 2 1533,8529 205 217
KVESLQEEIAFLKK R L 95,00% 3,18 0,398 2,89 0 1 0 0 2 1661,9479 205 218
LGDLYEEEMR R E 95,00% 3,22 0,464 5,32 0 4 0 0 2 1270,5627 128 137
LQDEIQNMK R E 95,00% 2,12 0,149 2,47 0 1 0 0 2 1134,5466 347 355
LQDEIQNMKEEMAR R H 95,00% 1,96 0 4,55 0 0 1 0 2 1766,8054 347 360
LQEEMLQR K E 95,00% 2,57 0,0424 1,8 0 1 0 0 2 1062,5255 171 178
LQEEMLQREEAESTLQSFR K Q 95,00% 3,24 0,308 6,82 0 0 1 0 2 2340,1143 171 189
MALDIEIATYR K K 95,00% 3,7 0,429 3,77 0 1 0 0 2 1311,662 373 383
NLQEAEEWYK K S 95,00% 2,68 0,224 4,89 0 5 0 0 2 1309,6066 265 274
QDVDNASLAR R L 95,00% 2,71 0,385 6,07 0 7 0 0 2 1088,5337 190 199
QVDQLTNDKAR R V 95,00% 0 0 4 0 2 0 0 2 1270,6394 142 152
QVQSLTCEVDALK R G 95,00% 0 0 4,07 0 1 0 0 2 1473,7262 304 316
QVQSLTCEVDALKGTNESLER R Q 95,00% 0 0 5,43 0 4 1 0 2 2360,1404 304 324
SLYSSSPGGAYVTR R S 95,00% 2,95 0,356 11,2 0 8 0 0 2 1444,707 33 46
TNEKVELQELNDR R F 95,00% 3,62 0,358 6,8 0 3 1 0 2 1587,798 83 95
TVETRDGQVINETSQHHDDLE K - 95,00% 2,88 0,22 1,27 0 0 3 0 2 2423,1072 428 448
VELQELNDR K F 95,00% 2,57 0,114 3,7 0 2 0 0 2 1115,5698 87 95
Vimentin (Fragment) - Cricetulus griseus (Chinese hamster) VIME_CRIGR 51831,8 100,00% 21 46 60 5,95% 44,00% DGQVINETSQHHDDLE R - 95,00% 3,55 0,345 4,25 0 4 1 0 2 1836,8002 433 448
EEAESTLQSFR R Q 95,00% 2,46 0,289 2,18 0 1 0 0 2 1296,6072 179 189
EEAESTLQSFRQDVDNASLAR R L 95,00% 0 0 7,08 0 0 1 0 2 2366,1221 179 199
ETNLESLPLVDTHSK R R 95,00% 3,54 0,42 6,41 0 1 0 0 2 1682,8602 407 421
EYQDLLNVK R M 95,00% 2,06 0,261 3,42 0 2 0 0 2 1121,5845 364 372
FADLSEAANR K N 95,00% 3,05 0,147 5,28 0 4 0 0 2 1093,5278 277 286
ILLAELEQLK K G 95,00% 3,61 0,217 4,24 0 2 0 0 2 1169,7148 112 121
ILLAELEQLKGQGK K S 95,00% 2,39 0,126 4,14 0 0 3 0 2 1539,9114 112 125
ISLPLPNFSSLNLR R E 95,00% 1,67 0,144 2,52 0 3 0 0 2 1570,8957 393 406
KVESLQEEIAFLK R K 95,00% 5,21 0,369 8,35 0 1 2 0 2 1533,8529 205 217
LGDLYEEEMR R E 95,00% 0 0 5,34 0 3 0 0 2 1254,5679 128 137
LGDLYEEEMRELR R R 95,00% 1,99 0,166 4,33 0 0 2 0 2 1668,7905 128 140
LLEGEESR K I 95,00% 2,54 0,122 3,55 0 2 0 0 2 932,4689 385 392
MALDIEIATYR K K 95,00% 1,84 0 2,8 0 3 0 0 2 1311,662 373 383
NLQEAEEWYK K S 95,00% 2,71 0,406 5,55 0 5 0 0 2 1309,6066 265 274
QDVDNASLAR R L 95,00% 2,34 0,355 3,77 0 7 0 0 2 1088,5337 190 199
QQYESVAAK R N 95,00% 0 0 3,46 0 2 0 0 2 1006,4845 256 264
QVQSLTCEVDALK R G 95,00% 3,68 0,425 6 0 4 0 0 2 1490,7527 304 316
QVQSLTCEVDALKGTNESLER R Q 95,00% 2,88 0,346 1,66 0 0 3 0 2 2377,167 304 324
TNEKVELQELNDR R F 95,00% 2,5 0,198 0,444 0 0 3 0 2 1587,798 83 95
VELQELNDR K F 95,00% 2,92 0,126 4,92 0 1 0 0 2 1115,5698 87 95
 at V
rije Universiteit--Amsterdam on April 3, 2012
http://circres.ahajournals.org/
D
ow
nloaded from
 
Online Table II: qPCR Primers and Probes 
 
Target 5´-Primer TaqMan Probe ( 5´-FAM, 3´-TAMRA)  3´-Primer 
GAPDH AAC TCC CTC AAG ATT GTC AGC AA ATG GAC TGT GGT CAT GAG CCC TTC CA CAG TCT TCT GAG TGG CAG TGA TG 
CSQ2 TTT CTG ACG GAG ACG TTC AGG TGG CTG CCT ACA GTA CGC TGG GAA C TAG CAG GAC AGA GAG GGT GCA 
α-cd actin TGA TGC TCC CAG AGC TGT CTT CCA CGC CAC CAG GGT GTC ATG GTA GAT GCC TCG CTT GCT CTG AG 
α-sk actin TAT GAG GGT TAT GCC CTG CC AAT CTC ACG TTC AGC TGT GGT CAC GAA GG GCT TCT CTT TGA TGT CGC GC 
α-MHC ACA GAG TGC TTC GTG CCT GAT ACA GTC ACC GTC TTG CCG TTT TCA GT CGA ATT TCG GAG GGT TCT GC 
β-MHC GCC TAC AAG CGC CAG GCT TTC ATT CAG GCC CTT GGC GCC AAT CAT CCT TAG GGT TGG GTA GCA 
bax ATC CAC CAA GAA GCT GAG CG ATC AGC AAT CAT CCT CTG CAG CTC CA ACG GAA GAA GAC CTC TCG GG 
Bcl-2 CCT GGT GGA CAA CAT CGC T AAC GGA GGC TGG GAT GCC TTT GTG AAT CAA ACA GAG GTC GCA TGC 
VEGF-A ACT GCT GTA CCT CCA CCA TGC AAG TGG TCC CAG GCT GCA CCC A AAG ATG TCC ACC AGG GTC TCA 
Collagen α1(I) TGG TCC TCA AGG TTT CCA AG TGG CGG TTC AGG TCC AAT GG TTA CCA GCT TCC CCA TCA TC 
Collagen α1(III) AAT GGT GGC TTT CAG TTC AGC T TGG AAA GAA GTC TGA GGA AGG CCA GCT G TGT AAT GTT CTG GGA GGC CC 
MMP-2 CCGAGGACTATGACCGGGATAA TCTGCCCCGAGACCGCTATGTCCA CTTGTTGCCCAGGAAAGTGAAG 
MMP-3 CCGTTTCCATCTCTCTCAAGATGA AGATGGTATTCAATCCCTCTATGGACCTCC CAGAGAGTTAGATTTGGTGGGTACCA 
MMP-13 GGAAGACCCTCTTCTTCTCA TCTGGTTAGCATCATCATAACTCCACACGT TCATAGACAGCATCTACTTTGTC 
MMP-14 GAACTTTGACACCGTGGCCAT CAGAACCATCGCTCCTTGAAGACAAACATC CCGTCCATCACTTGGTTATTCCT 
TIMP-1 TCCTCTTGTTGCTATCATTGATAGCTT TTCTGCAACTCGGACCTGGTTATAAGG CGCTGGTATAAGGTGGTCTCGAT 
TIMP-2 GCTGGACGTTGGAGGAAAGA TCTCCTTCCGCCTTCCCTGCAATTAGA GCACAATAAAGTCACAGAGGGTAAT 
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Online Figure I.  Quantification of cardiomyocytes and fibroblasts during EHT culture by flow 
cytometry.  Representative plots identify distinct a-actinin- (A) and vimentin-positive cell 
populations (B) at the indicated days of EHT culture.  Panels resemble overlays of individual dot 
plots: in red cell pools labeled for actinin (A) or vimentin (B); in grey cell pools exposed to secondary 
antibody only.
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Online Figure II.  DNA content in mononucleated cardiomyocytes and 
fibroblasts during EHT culture assessed by FACS.  A, Representative plots of 
DNA content in mononucleated cardiomyocytes (actinin-positive, red) and non-
myocytes (actinin-negative, dark grey) at day 0 and day 12 of EHT culture.  B, 
Fractions of mononucleated cardiomyocyte (top panel) and non-myocyte (lower 
panel) populations at day 0 (n=6) and day 12 (n=4) of EHT culture with 2N, 4N, and 
8N DNA content.
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Online Figure III
Online Figure III.  Surrogate parameters suggesting hypertrophic growth in EHTs.  A, RNA/DNA ratio in EHTs 
3on culture days 0 (n=18), 3 (n=19), 7 (n=10), and 12 (n=16).  B, H-phenylalanine incorporation during EHT culture 
days 0-3 (n=7), 3-7 (n=8), and 7-12 (n=5).  *P< 0.05 vs. EHT day 0 (A) and EHT days 0-3 (B); ANOVA and 
Bonferroni's multiple comparison test.
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Online Figure IV
Online Figure IV.  Cell death in EHT and monolayer (2D) culture.  A, Analysis of DNA content in EHT- and 2D culture-
derived cells (n=3 each).  Sub-G1 fraction (green) denotes dead/apoptotic cells with condensed nuclei.  B, Trypan-blue 
exclusion in EHT- and 2D culture-derived cells at culture day 1 (n=5 [EHT], n=4 [2D]).  C, Comparison of CSQ2 transcript 
abundance in EHT (black bars) vs. 2D culture (white bars), n=5-6/time-point.  *P<0.05 vs. day 0 (grey bar); ANOVA and 
Bonferroni’s multiple comparison test.
 at Vrije Universiteit--Amsterdam on April 3, 2012http://circres.ahajournals.org/Downloaded from 
A
N
P
/G
A
P
D
H
0
2
4
6
8
0
1
2
S
ke
le
ta
l s
ct
in
/C
S
Q
2
Neonatal 
(d0)
2D 
(d12)
EHT 
(d12)
Neonatal 
(d0)
2D 
(d12)
EHT 
(d12)
0
5
10
15
Neonatal 
(d0)
C
ar
di
ac
 s
ct
in
/C
S
Q
2
0
10
20
30
C
ar
di
ac
 a
ct
in
1 2 3 4
Skeletal actin
0
EHT (d12) 2D (d12)
1 2 3 4
Skeletal actin
0
0
10
20
30
C
ar
di
ac
 a
ct
in
D
1 2 3 4
Skeletal actin
0
0
10
20
30
C
ar
di
ac
 a
ct
in
2D 
(d12)
EHT 
(d12)
10 * * 20A B C
d12
d7
d3
Neonatal (d0)
d3
d7
d12
Online Figure V
Online Figure V.  Molecular markers of maturation in 2D vs. EHT culture.  A, ANP transcripts per GAPDH transcript; B, skeletal actin transcripts 
per GAPDH transcript; C, cardiac actin transcripts per GAPDH transcript in isolated neonatal heart cells at day 0 (black bars; n=5), 2D cultured cells at 
day 12 (blue bars; n=6), and EHT at day 12 (green bars; n=5).  D, Correlation of cardiac and skeletal actin transcript abundance in freshly isolated 
neonatal heart cells (d0; black), in 2D culture (culture days 3,7, and 12 [left panel]) and EHT culture (culture days 3, 7, and 12 [middle panel]) - black 
arrows denote the trend in expression pattern change in 2D and EHT culture; right panel:  direct comparison of 12 day 2D vs. EHT cultures and 
neonatal cardiomyocytes.  *P<0.05 2D vs. EHT; Student’s t-test..
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Online Figure VI
Online Figure VI.  ECM restructuring during EHT-development.  A, matrix 
metalloprotease-2 (MMP-2; n=8-10); B, MMP-14 (n=7-10); tissue inhibitor of matrix 
metalloprotease-1 ( TIMP-1; n=7-10), and TIMP-2 (D; n=7-10) transcripts per GAPDH 
transcript in EHT and native rat heart tissue.  *P<0.05 vs. EHT day 0; ANOVA followed by 
Bonferroni's multiple comparison test. 
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Online Figure VII
Online Figure VII.  Development of a cardiomyocyte-specific qPCR assay to allow approximation of 
cardiomyocyte content in mixed cell populations.  Detection of CSQ2 (NCBI accession#: AF001334; 
6squares) and GAPDH (NCBI accession#: NC005103; circles) transcripts in 2.5x10  cells containing the 
indicated cardiomyocyte fraction by qPCR.  High Ct-values indicate low transcript abundance.  Symbols 
indicate individual Ct-values.  Bars indicate the respective means.  A Ct-value difference of 3.3 ideally 
represents a 10-fold difference in transcript abundance.  Similar data could be obtained using alternative 
primer-probe pairs for muscle specific CSQ2 (Ensemble accession#: ENSRNOG00000016243) or 18S-RNA 
(NCBI accession#: V01270).
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